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ABSTRACT 
Evolution by natural selection and the overuse of antibiotics have led to the emergence 
and proliferation of drug-resistant bacteria. One of the mechanisms that bacteria have evolved to 
overcome antibiotics is the membrane efflux pump. By expelling the drugs outside of the cell, 
the bacterium prevents the molecule from accumulating to a toxic level. Transcriptional 
regulators, which control when the genes of these proteins are transcribed from DNA to RNA, 
are able to sense the drugs within the cell by binding to them. In the transcriptional repression 
process, once ligand-bound, the regulators are released from the DNA, allowing the efflux 
protein to be expressed. The efflux pump then recognizes these drugs and pumps them out of the 
cell. Both the regulator and the protein that it regulates recognize the same drugs. In fact, most of 
these are able to recognize multiple drugs or drug classes, making treatment difficult. 
In this thesis, we examine the protein structure to determine its function and to predict its 
reaction to new substrates. We determined the X-ray crystal structures of the transcriptional 
regulator Rv3066 from Mycobacterium tuberculosis and two components of the MtrCDE 
tripartite pump (MtrD and MtrE) from Neisseria gonorrhoeae, and examined the tripartite efflux 
complex CusCBA to determine the mechanism behind ion extrusion. To better understand how 
the regulators and efflux pumps recognize their substrates, we used AutoDock Vina to predict 
binding sites and to predict possible new ligands. With this data, we hope to find a way to 
impede the resistance of bacteria to drugs and allow existing antibiotics to become effective 
again.  
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CHAPTER I 
 INTRODUCTION 
 A history of antibiotics 
Before the advent of antibiotics—agents that kill or inhibit bacteria—in the 1930’s, 
bacterial infections would routinely become death sentences. Mycobacterium tuberculosis, the 
bacteria responsible for tuberculosis, was one of the leading causes of death in the United States 
and Europe in the early 1900’s (1). Without antibiotics, a small cut or scrape can be fatal if 
Staphylococcus aureus, a bacterium commonly found on skin, finds its way into the body. The 
first commercially available antibiotic, Prontosil, in 1935, ushered in the golden era of 
antibiotics. Prontosil was the first sulfonamide drug, introduced as a cure for the illness puerperal 
fever caused by the Gram-positive bacteria Streptococcus pyogenes (2).  
Sulfanilamide’s (another sulfonamide drug) effect as an antibiotic was discovered shortly 
after and introduced into the pharmaceutical market in 1936. As a simpler and easier to produce 
drug, it eclipsed Protosil’s importance. Gerhard Domagk, who discovered the significance of 
Prontosil and sulfonamides, was awarded the Nobel Prize in Medicine for this discovery (3). 
Although penicillin became popular in the early 1940’s due to its better effects and fewer side 
effects, Domagk’s continued work on sulfonamides lead to the development of antituberculosis 
drugs such as thiosemicarbazone and isoniazid (4).  
Although the discovery of penicillin by Alexander Fleming was in 1928 (5), it was not 
tested as a treatment for bacterial infections until two years later, when Cecil George Paine 
treated a type of gonococcal infection in infants (6). Even then, the purification and manufacture 
of the drug was time and resource consuming, and it was not until the early 1940’s that it was 
made in sufficient amounts to be used in the military during World War II (7).   
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This era, from the 1940’s to the 1960’s, saw the invention of many new types of 
antibiotics. The aforementioned antibiotic classes of sulfonamides and penicillin were the first of 
many. The first of the peptide, aminoglycoside, tetracycline, and amphenicol antibacterial classes 
were discovered in the 1940’s. The discovery of new classes continued into the 1950’s with 
glycopeptide and polymyxin antibiotics. The 1960’s was an especially prolific decade, with 
nitroimidazole, dihydrofolate reductase inhibitor, cephalosporin, quinolone, and lincosamide 
antibiotics discoveries (8). 
The introduction of new classes of antibiotics slowed in the 1970’s, however. At this 
point, the emphasis was on modifying the known antibiotics in order to reduce side effects. The 
next class was not until 1985 with the first carbapenem (8). Due to the costs of traditional 
antibiotic research and the lower returns—newer drugs were relegated to last-line-defense in 
order to keep antibiotic resistance at bay—pharmaceutical companies either dedicated their 
resources to improving available drugs or to more profitable drugs such as painkillers (9). Very 
few new antibiotic classes have been discovered since then, which is problematic with the 
growing concern of antibiotic resistant bacteria. 
The emergence of antibiotic resistant bacteria 
Sir Alexander Fleming’s Nobel Prize lecture in 1945 predicted the emergence of 
antibiotic-resistant bacteria and the route that it would take: Under-dosage of antibiotics would 
allow the natural selection of resistant bacteria (10). Even with this warning, penicillin-resistant 
Staphylococcus bacteria appeared only a year after its initial use during World War II and its 
introduction to the public. It took less than a decade from the first commercial sulfonamide to the 
first documented sulfonamide-resistant bacteria (8). 
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At that point in time, antibiotic resistance was not given the attention it deserved. New 
antibiotics were discovered as quickly as the bacteria were evolving. As the discoveries slowed 
however, the bacteria had time to catch up. Because antibiotics became the panacea for all 
illnesses regardless of its effect, many new antibiotic-resistant strains emerged. In the 1960’s 
bacterial strains resistant to many of the first-line treatments emerged. With so few new 
antibacterial drugs to counteract this trend, there is a real possibility of returning to a pre-
antibiotic world. 
Resistance mechanisms 
 Bacteria were one of the first life forms on Earth, and they adapt quickly and well to new 
environments. While most bacteria are harmless to humans, the pathogenic ones are the ones of 
utmost concern and the best studied. Cholera, leprosy, tuberculosis, gonorrhea, Lyme disease, 
and the Black Plague are all caused by bacterial infections and had been well controlled by the 
advent of antibiotics.  
Bacteria have several mechanisms that are used to reduce the efficacy of antibacterial 
drugs. The first defense is the cell wall. The cell wall may be impermeable to the drugs or it 
lacks the proper transport system into the bacterial cell; an example is the outer membrane of 
Gram-negative bacteria (11). Another mechanism is the deactivation of the drug through 
modification. Some penicillin-resistant bacteria break the drug’s structure by producing β-
lactamase enzymes (12).  Other methods include modifying the drug targets themselves. A slight 
modification to the terminal end of vancomycin’s peptide target causes a significant loss of 
affinity, allowing the cell wall to form cross-links where it would have otherwise fallen apart 
(13).  
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Finally, there are there are the efflux pumps. Bacterial efflux pumps confer resistance by 
preventing the drug from accumulating within the cell. These active transporters use an energy 
source to pump various materials through the cell membrane. These pumps can be specific for a 
ligand or it can recognize several ligands, allowing it to be more effective (14). Because they are 
integral membrane proteins, their structures are more difficult to determine than soluble proteins. 
As a result, the mechanisms behind these efflux pumps are not as well studied as the other 
resistance mechanisms. 
Bacterial efflux pumps 
 Resistant bacteria can, and often do, have multiple efflux pumps that prevent the 
accumulation of toxic materials inside the cell. By understanding the mechanisms behind these 
pumps, drugs can be designed that can allow current first-line antibiotic treatments to be 
effective once again. The transmembrane efflux pumps are categorized into five major 
superfamilies based on their amino acid sequence and their energy source: 
The ATP-Binding Cassette superfamily (ABC) uses ATP to pump substrates across the 
bacterial membrane (15). The largest transporter family, ABC superfamily proteins are able to 
transport specific or groups of substrates across the cell membrane. Known substrates in bacteria 
include bile acids (16), metal ions (17), and various antibiotics (18). This transporter is one of the 
two families to occur ubiquitously in all living organisms. The mammalian proteins ABCC1 (19) 
and ABCC2 (19), for example, may confer chemotherapeutic drug resistance to tumor cells. 
The Major Facilitator Superfamily (MFS), which includes proton-pumps that transport 
small substrates, is the other family that is ubiquitous in living organisms (20). Unlike the ABC 
transporters, the MFS transporters only facilitate the efflux of small solutes. Within this 
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superfamily are distinct families that transport specific classes of compounds, including simple 
sugars (20) (21), drugs, and ions (20).  
The Multidrug And Toxic compound Extrusion (MATE) protein family is a Na
+
-coupled 
transporter found in bacteria, archaea, and eukaryotes. MATE proteins confer resistance to 
cationic dyes, fluroquinolones, antibodies, and other drugs (22).    
The Small Multidrug Resistance (SMR) family uses a proton pump. True to their name, 
these proteins are relatively small at 100-140 amino acids in length. They transport and confer 
resistance to lipophilic compounds as well as some antibiotics (23). 
The Resistance Nodulation cell Division (RND) superfamily incorporates a proton 
antiport mechanism in order to move substrates. This family is especially interesting in that it is 
comprised of multiple subunits spanning the inner and outer membranes. The inner membrane 
protein acts as a pump, pushing substrates through the inner membrane, and out the outer 
membrane through the outer membrane protein. Connecting these two is the membrane fusion 
protein (MFP), a periplasmic protein (24).  
RND systems are further categorized into the Hydrophobic and Amphiphilic Efflux RND 
(HAE-RND) and the Heavy Metal Efflux RND (HME-RND) subfamilies (25) (26). The HAE-
RND systems are multidrug efflux pumps whereas the HME-RND systems pump heavy metals. 
The bacterium Escherichia Coli has seven RND proteins—six HAE-RND proteins and one 
HME-RND.  In E. Coli, the HAE-RND proteins (those in the inner membrane) are AcrB (27) 
(28) (29) (30), AcrD (28) (31) (32), AcrF (28) (33), MdtB (28) (34), MdtC (28) (34), and YhiV 
(28) (35). The lone HME-RND protein is CusA (36) which pumps Cu(I) and Ag(I) ions. These 
are connected to the outer membrane protein by the MFP. All of the HAE-RND proteins use the 
same outer membrane protein, TolC, whereas the HME-RND protein uses CusC.    
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The crystal structures have only been determined for several RND proteins: AcrA (37), 
AcrB (38), MexA (39), MexB (40), TolC (41), OprM (42), CusA (43), CusB (44), and CusC 
(45). While there are different ways to derive the structure of proteins, X-ray crystallography has 
been the standard due to its ability to determine larger proteins at higher resolutions. The 
structure of a protein can reveal much about its mechanisms: its binding regions, its movement, 
and its interactions with other proteins. As seen later in this thesis, the structure of Rv3066 at 
2.3 Å was enough to determine specific mechanisms that the protein used to bind to its substrate. 
Gene regulation 
To conserve the energy and resources needed for survival, the expression of these efflux 
pumps are tightly regulated at the transcriptional level.  The presence of the proper substrates 
causes the transporters to be expressed. In one method to do this, regulatory proteins called 
repressors are bound to the promoter region of the gene, preventing RNA polymerase from 
attaching to the DNA. Once the correct substrate—oftentimes, the same substrate that the 
expressed protein recognizes and transport to across the bacterial memrbane—binds to the 
repressor, the protein undergoes a conformational change and is no longer bound to the DNA, 
thus allowing the gene to be transcribed and the protein to be expressed.  
Many of the known bacterial transcriptional regulators share the helix-turn-helix (HTH) 
structural motif used to bind their target DNA (46). These regulators are classified into families 
based on their functional and sequence similarities. The Tetracycline transcriptional Regulator, 
or TetR, was the first protein of its family found, and the family of regulator is still named after 
it. The TetR family of regulators are homodimers with N-terminal HTH binding motifs and C-
terminal binding regions (47). Most structures in this family are comprised of nine-α helices per 
protomer, but there are some exceptions such as CmeR.  
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Computational biology 
The age of computers added a new tool to the field of biology and drug screening. 
Originally, new antibiotics were screened for one by one. However, this is a costly and time-
consuming method, and one of the reasons why pharmaceutical companies do not pursue new 
antibacterial targets. With the crystal structure of the target protein and a library of drug 
structures, possible binding ligands can be found in less time and using fewer resources. After 
the virtual search, the screening target list is narrowed, allowing a more focused approach to 
finding drugs.  
An example is with the popular docking program, AutoDock (48), by Arthur Olson. 
AutoDock was used by J. Andrew McCammon and colleagues to find new ways to inhibit HIV 
intergrases; as a result of their work, the pharmaceutical company Merck was able to design new 
drugs to target this integrase. In 2007, this work led to the FDA approval of the HIV integrase 
inhibitor raltegravir (49). With the crystal structure of efflux pumps, it may be possible to design 
new drugs that can either inhibit the expression of these pumps or the function of the pumps 
themselves. 
In Chapter 2, we start with the transcriptional regulator Rv3066. The protein Rv3066 
binds to an inverted repeat upstream of the mmr gene, which is part of the mmr-rv3066 operon. 
The mmr protein confers to M. tuberculosis reisistance to cationic dyes and inhibitors such as 
tetraphenylphosphonium, erythromycin, ethidium bromide, and acriflavine. The determination of 
the apo-form and the bound form of this protein allowed us to propose a DNA-binding 
mechanism and to predict how the regulator recognizes one of its substrates.  
In Chapter 3, we look at the crystal structures of the CusCBA efflux system. This 
tripartite complex expels the heavy metals Cu(I) and Ag(I) in E. coli. The chapter goes over the 
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separate structures as well as the bound structure of CusBC. We look at the ion-relay network 
that is used by CusA to extrude metal ions, and how the three proteins work as a unit to expel 
said ions. 
Chapter 4 goes over the structure of MtrD and its docking study. MtrD is a 
transmembrane efflux pump in N. gonorrhoeae that, along with MtrC and MtrE, confers 
resistance to hydrophobic agents such as bile salt and fatty acids.  We look closer at the use of 
AutoDock to study the possible binding sites in MtrD. Using the Sigma Aldrich database of 
available chemicals, we try to find the best binding site and the possible ligands for this site. Due 
to their relativity, these two chapters were combined. In addition, we predicted the structure of 
the periplasmic protein MtrC to examine how the three proteins may interact. 
Chapter 5 comprises the conclusion. 
 
References 
1. Morbidity and Mortality Weekly Report: Achievements in Public Health, 1900-1999: 
Control of Infectious Diseases. (1999) Available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm. 
Description: Review on public health and how illness and infection treatments have 
improved since 1900. Accessed 13 May 2014.  
 
2. Foulis, M.A. and Barr, J. B. (1937) Prontosil Album in Puerperal Sepsis. The British 
Medical Journal, Vol. 1, pp. 445-446. 
 
3. Nobel Media AB. The Nobel Prize in Physiology or Medicine 1939. (1939) Available at 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1939. 
Description: Note on the winner of the 1939 Nobel prize in Physiology or Medicine. 
Accessed 13 May 2014. 
 
4. Gerhard Domagk - Biographical. (1965) Available at 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1939/domagk-bio.html. 
Description: Biography of Gerhard Domagk, winner of the 1939 Nobel Prize in 
Physiology or Medicine. Accessed 13 May 2014. 
 
 
9 
 
5. Nobel Media AB. Sir Alexander Fleming – Biographical. (1964) 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-bio.html.  
Description: Biography of Alexander Fleming, winner of the 1945 Nobel Prize in 
Physiology or Medicine. Accessed 13 May 2014. 
 
6. Wainwright, M. and Swan, H.T. C.G. Paine and the Earliest Surviving Clinical Records 
of Penicillin Therapy. (1986) Medical History, Vol. 30, pp. 42-56. 
 
7. American Chemical Society International Historic Chemical Landmarks. Discovery and 
Development of Penicillin. Available at 
http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicilli
n.html. 
Description: History of penicillin. Accessed 13 May 2014. 
 
 
8. Antibiotic Resistance Timeline. ( 2013) Available at  
http://lumibyte.eu/medical/antibiotic-resistance-timeline. 
Description: Timeline of antibiotic resistance. Accessed 13 May 2014. 
 
9. Clarke, T. Drug companies snub antibiotics as pipeline threatens to run dry. (2011) 
Available at  http://www.nature.com/drugdisc/news/articles/425225a.html. 
Description: Reasons whey major drug companies are not investing in new antibiotics. 
Accessed 13 May 2014. 
 
10. Fleming, A. Penicillin. 1945. Nobel Lecture.  
 
11. Costerton, J.W., Ingram, J.M. and Cheng, K.J.Structure and function of the cell envelope 
of gram-negative bacteria. (1974) Bacteriol Rev, Vol. 38, pp. 87-110.  
 
12. Wilke, M.S., Lovering, A.L. and Strynadka, N.C.J. β-Lactam antibiotic resistance: a 
current structural perspective. (2005) Current Opinion in Microbiology, Vol. 8, pp. 525–
533. 
 
13. Pootoolal, J., Neu, J. and Wright, G.D. Glycopeptide Antibiotic Resistance.(2002) nnual 
Review of Pharmacology and Toxicology, Vol. 42, pp. 381-408.  
 
14. Poole, K. Efflux pumps as antimicrobial resistance mechanisms.(2007) Annals of 
Medicine, Vol. 39, pp. 162-176.  
 
15. Higgins, C.F. ABC transporters: physiology, structure and mechanism – an overview. 
(2001) Res. Microbiol., Vol. 152, pp. 205–210. 
 
16. Zaidi, A.H., Bakkes, P.J., Luvelski, J., Agustiandari, H., Kuipers, O.P. and Driessen, 
A.J.M. The ABC-Type Multidrug Resistance Transporter LmrCD Is Responsible for an 
Extrusion-Based Mechanism of Bile Acid Resistance in Lactococcus lactis. (2008) 
Journal of Bacteriology, Vol. 190, pp. 7357–7366. 
10 
 
 
17. Claverys, J.P. A new family of high-affinity ABC manganese and zinc permeases. (2001) 
Research in Microbiology, Vol. 152, pp. 231-43. 
 
18. Dawson, R.J.P., Hollenstein, K. and Locher, K.Uptake or extrusion: crystal structures of 
full ABC transporters suggest a common mechanism. (2007) Molecular Microbiology, 
Vol. 65, pp. 250-257. 
 
19. Soucek, P. and Kunicka T. Importance of ABCC1 for cancer therapy and 
prognosis.(2014) Drug Metabolism Review, pp. 1-18. 
 
20. Pao, S.S., Paulsen, I.T. and Saier Jr., MH. Major Facilitator Superfamily. (1998) 
Microbiology and Molecular Biology Reviews, Vol. 62, pp. 1-34. 
 
21. Zhang, W., Kou, Y., Xu, J., Cao, Y., Zhao, G., Shao, J., Wang, H., Wang, Z., Bao, W., 
Chen G. and Liu, W. Two major facilitator superfamily sugar transporters from 
Trichoderma reesei and their roles in induction of cellulase biosynthesis. (2013) Journal 
of Biological Chemistry, Vol. 288, pp. 32861-32872. 
 
22. Moriyama, Y., Hiasa, M., Matsumoto, T. and Omote, H. Multidrug and toxic compound 
extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic 
waste products and xenobiotics.(2008) Xenobiotica, Vol. 38, pp. 1107-1118. 
 
23. Bay, D.C., Rommens, K.L. and Turner R.J. Small multidrug resistance proteins: A 
multidrug transporter family that continues to grow. (2008) Biochimica et Biophysica 
Acta (BBA) - Biomembranes, Vol. 1778, pp. 1814-1838. 
 
24. Nikaido, H. Structure and Mechanism of RND-Type Multidrug Efflux Pumps. (2011) 
Adv Enzymol Relat Areas Mol Biol, Vol. 77, pp. 1–60. 
 
25. Tseng, T.T., Gratwick, K.S., Kollman, J., Park, D., Nies, D.H., Goffeau, A. and Saier, Jr., 
M.H. The RND Permease Superfamily: an Ancient, Ubiquitous and DIverse Family that 
includes Human Disease and Development Protein. (1999) Journal of Molecular 
Microbiology and Biotechnology, Vol. 1, pp. 107-125. 
 
26. Nies, D.H. Efflux-mediated Heavy Metal Resistance in Prokaryotes. (2003) FEMS 
Microbiol. Rev, Vol. 27, pp. 313-339. 
 
27. Zgurskaya, H.I. and Nikaido, H. Bypassing the periplasm: Reconstitution of the AcrAB 
multidrug efflux pump of Escherichia coli. (1999) PNAS, Vol. 96, pp. 7190–7195. 
 
28. Nishino, K. and Yamaguchi, A. Analysis of a Complete Library of Putative Drug 
Transporter Genes in Escherichia coli. (2001) Journal of Bacteriology, Vol. 183, pp. 
5803-5812. 
  
11 
 
 
29. Muramaki, S., Nakashima, R., Yamashita, E. and Yamaguchi, A. Crystal structure of 
bacterial multidrug efflux transporter AcrB. (2002) Nature, Vol. 419, pp. 587-593. 
 
30. Yu, E.W., McDermott, G., Zgurskaya, H.I., Nikaido, H. and KOshland, Jr., D.E. 
Structural Basis of Multiple Drug-Binding Capacity of the AcrB Multidrug Efflux Pump. 
(2003) Science, Vol. 300, pp. 976-980. 
 
31. Rosenberg, E.Y., Ma, D., and Nikaido H. AcrD of Escherichia coli is an aminoglycoside 
efflux pump. (2000) Journal of Bacteriology, Vol. 182, pp. 1754-1758.  
 
32. Aires, J.R. and Nikaido, H. Aminoglycosides are captured from both periplasm and 
cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. (2005) Journal of 
Bacteriology, Vol. 187, pp. 1923-1929. 
 
33. Ma, D., Cook, D.N., Alberti, M., Pon, N.G., Nikaido, H. and Hearst, J.E. Molecular 
Cloning and Characterization of acrA and acrE. (1993) Journal of Bacteriology, Vol. 175, 
pp. 6299-6313. 
 
34. Baranove, N. and Nikaido, H. The baeSR two-component regulatory system activates 
transcription of the yegMNOB (mdtABCD) transporter gene cluster in Escherichia coli 
and increases its resistance to novobiocin and deoxycholate. (2002) Journal of 
Bacteriology, Vol. 184, pp. 4168-4176. 
 
35. Kobayashi, N., Nishino, K.and Yamaguchi, A. Novel Macrolide-Specific ABC-Type 
Efflux Transporter in Escherichia coli. (2001) Journal of Bacteriology, Vol. 183, pp. 
5639-5644. 
 
36. Franke, S., Grass, G. and Nies, D.H. The product of the ybdE gene of the Escherichia coli 
chromosome is involved in detoxification of silver ions. (2001) Microbiology, Vol. 147, 
pp. 965-972. 
 
37. Mikolosko, J., Bobyk, K., Zgurskaya, H.I. and Ghosh, P. Conformational flexibility in 
the multidrug efflux system protein AcrA. (2006) Structure, Vol. 14, pp. 577–587. 
 
38. Seeger, M.A., Schiefner, A., Eicher, T., Verry, F., Diederichs, K. and Pos, K.M. 
Structural Asymmetry of AcrB Trimer Suggests a Peristaltic Pump Mechanism. (2006) 
Science, Vol. 313, pp. 1295-1298. 
 
39. Akama, H., Matsuura, T., Kashiwagi, S., Yoneyama, H., Narita, S., Tsukihara, T., 
Nakagawa, A. and Nakae, T. Crystal structure of the membrane fusion protein, MexA, of 
the multidrug transporter in Pseudomonas aeruginosa. (2004) J.Biol.Chem, Vol. 279, pp. 
25939-25942. 
  
12 
 
 
40. Sennhauser, G., Bukowska, M.A., Briand, C. and Gruetter, M.G. Crystal structure of the 
multidrug exporter MexB from Pseudomonas aeruginosa. (2009) J.Mol.Biol. , Vol. 389, 
pp. 134-145. 
 
41. Koronakis, V., Sharff, A., Koronakis, E., Luisi, B., Hughes, C. Crystal structure of the 
bacterial membrane protein TolC central to multidrug efflux and protein export. 2000 
Nature, Vol. 405, pp. 914-919. 
 
42. Akama, H., Kanemaki, M., Yoshimura, M., Tsukihara, T., Kashiwagi, T., Yoneyama, H., 
Narita, S. and Nakagawa, A., Nakae, T. Crystal structure of the drug discharge outer 
membrane protein, OprM, of Pseudomonas aeruginosa: dual modes of membrane 
anchoring and occluded cavity end. (2004) J.Biol.Chem, Vol. 279, pp. 52816-52819. 
 
43. Long, F., Su, C.C., Zimmermann, M.T., Boyken, S.E., Rajashankar, K.R., Jernigan, R.L. 
and Yu, E.W. Crystal structures of the CusA efflux pump suggest methionine-mediated 
metal transport. (2010) Nature, pp. 484-488. 
 
44. Su, C.C., Yang, F., Long, F., Reyon, D., Routh, M.D., Kuo, D.W., Mokhtari, A.K., Van 
Ornam, J.D., Rabe, K.L., Hoy, J.A., Lee, Y.J., Rajashankar, K.R. and Yu, E.W. Crystal 
structure of the membrane fusion protein CusB from Escherichia coli. (2009) J.Mol.Biol, 
Vol. 393, pp. 342-355. 
 
45. Kulathila, R., Kulathila, R., Indic, M. and van den Berg, B. Crystal structure of 
Escherichia coli CusC, the outer membrane component of a heavy metal efflux pump. 
(2011) Plos One, Vol. 6, pp. e15610-e15610. 
 
46. Aravind, L., Anantharaman, V., Balaji, S., Babu, M.M. and Iyer, L.M. The many faces of 
the helix-turn-helix domain: transcription regulation and beyond. (2005) FEMS 
Microbiology Reviews, Vol. 29, pp. 231–262. 
 
47. Ramos, J.L., Martinez-Bueno, M., Molina-Henares, A.J., Terán, W., Watanabe, K., 
Zhang, X., Gallegos, M.T., Brennan, R. and Tobes, R. The TetR family of transcriptional 
repressors. (2005) MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, Vol. 
69, pp. 326–356. 
 
48. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. 
and Olson, A. J. Autodock4 and AutoDockTools4: automated docking with selective 
receptor flexiblity. (2009) J. Computational Chemistry, Vol. 16, pp. 2785-91. 
 
49. AutoDock's role in Developing the First Clinically-Approved HIV Integrase Inhibitor. 
(2007) Available at http://autodock.scripps.edu/news/autodocks-role-in-developing-the-
first-clinically-approved-hiv-integrase-inhibitor.  
Description: Review on how AutoDock was used used in the discovery of an HIV-
integrase inhibitor. Accessed 13 May 2014. 
 
13 
 
 
CHAPTER 2 
Structural and functional analysis of the transcriptional regulator Rv3066 of 
Mycobacterium tuberculosis 
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Abstract 
The Mmr multidrug efflux pump in Mycobacterium tuberculosis recognizes and extrudes 
a broad range of antimicrobial agents, thus conferring to the bacterium resistance to said agents. 
The expression of the mmr gene is repressed by the TetR-family transcriptional regulator 
Rv3066. To understand the structural basis of the Rv3066 regulation, we determined the crystal 
structures of Rv3066 in the absence of a ligand and Rv3066 in the presence of bound ethidium. 
The two structures depict an asymmetric homodimeric two-domain molecule with an entirely 
helical architecture. Their differences underscore the ability of the regulator essential to 
recognize multiple drugs: the conformational change leading to the derepression of the mmr gene 
is due to a rigid body rotational motion within the dimer interface of the regulator. The regulator 
contains a multidrug-binding pocket containing five aromatic residues. The bound-ethidium is 
found within this pocket, where extensive aromatic stacking interactions, as well as hydrogen 
bonding, seemingly govern the protein-ligand interaction. In vitro studies reveal that the dimeric 
Rv3066 regulator binds to a 14-bp palindromic inverted repeat sequence in the nanomolar range.  
These findings provide new insight into the mechanisms of ligand binding and Rv3066-mediated 
regulation. 
Introduction 
 Tuberculosis (TB) is caused by the bacteria Mycobacterium tuberculosis. It is a 
highly contagious infection and is one of the most deadly infections. In 2009, the bacterium was 
responsible for 1.7 million deaths (1). The infection is difficult to treat, requiring six months of a 
combination of medications, which increases the chances of drug-resistance in the bacteria. 
Some M. tuberculosis strains have already developed resistance to commonly used anti-TB 
agents isoniazid and rifampicin.  
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The development of these drug resistant strains is mainly due to the mismatch between 
treatment and symptoms, such as the irregular intake of drugs throughout the course of treatment 
and inappropriate prescription of medications (2). Because of these problems, especially in 
developing nations, multi-drug resistant (MDR) (3, 4), extensively drug-resistant (XDR) (2, 5), 
and most recently totally drug-resistant (TDR) (6) strains of M. tuberculosis have emerged and 
spread globally. Although it has only been identified in three countries, TDR-TB is a huge 
concern because, currently, there are no treatments available. It is obvious that the emergence of 
these drug-resistant TB strains has evolved into a major threat and challenges our global 
prospects for TB control.  Thus, knowledge of the molecular mechanisms underlying drug 
resistance in M. tuberculosis is essential for the development of new strategies to combat this 
disease. 
  Recent evidence suggests that MDR strains of M. tuberculosis are associated with 
constitutive or inducible expression of multidrug efflux pumps (7).  These pumps have been 
classified into five different families: the ATP-binding cassette (ABC), resistance-nodulation-
division (RND), multidrug and toxic compound extrusion (MATE), major facilitator (MF), and 
small multidrug resistance (SMR) families (8).  It has been found that the genome of M. 
tuberculosis contains genes encoding efflux pumps from all these families (9, 10).  In addition, 
several of these MDR efflux pumps have been identified and characterized (9).  One such pump 
is the Mmr (Rv3065) multidrug efflux pump, which belongs to the SMR family (11).  Mmr has 
been shown to mediate resistance to many toxic compounds, including acriflavine, ethidium 
bromide, erythromycin, pyronin Y, safranin O, tetraphenylphosphonium, and thioridazine (11, 
12). 
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 Elucidating the regulatory systems of multidrug efflux pumps in M. tuberculosis should 
allow us to understand how this bacterium aquires multidrug resistance and how it adapts to 
environmental changes. Here, we report the crystal structures of the Rv3066 efflux regulator 
both in the absence and presence of bound ethidium, suggesting that ethidium binding triggers a 
rotational motion of the regulator.  This motion results in inducing the expression of the Mmr 
efflux pump by releasing the Rv3066 regulator from its cognate DNA at the promoter region.  
The rv3066 gene is located immediately downstream of mmr and encodes a 202 amino-acid 
protein that shares sequence homology to members of the TetR family of regulators (13, 14).  
Our data indicate that Rv3066 is a TetR-family regulator, which represses the transcription of 
mmr by directly binding to the inverted repeat (IR) of the promoter. 
Determination of the crystal structure of Rv3066 
After Bolla attained the protein crystals for the apo- and ethidium-bound Rv3066, 
diffraction data were collected at 100K at beamline 24ID-E located at the Advanced Photon 
Source, using an ADSC Quantum 315 CCD-based detector. Diffraction data were processed 
using DENZO and scaled using SCALEPACK (15).  The crystals of form I belong to space 
group P21212 (Table 1).  Based on the molecular weight of Rv3066 (22.78 kDa), a single dimer 
per asymmetric unit with a solvent content of 36.1% is expected.  Two selenium sites were 
identified using SHELXC and SHELXD (16) as implemented in the HKL2MAP package (17).  
Single-wavelength anomalous dispersion (SAD) phasing using the program PHASER (18) was 
employed to obtain experimental phases in addition to phases from the structural model of the 
EbrR regulator (residues 83-176) (PDB code: 3hta).  The resulting phases were then subjected to 
density modification and NCS averaging using the program PARROT (19).  The phases were of 
excellent quality and allowed for tracing of most of the molecule in PHENIX AutoBuild (20), 
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which led to an initial model containing 72% amino acid residues and 54% of which contained 
side-chains.  The remaining part of the model was manually constructed using the program Coot 
(21).  Then, the model was refined using TLS refinement techniques adopting a single TLS body 
as implemented in PHENIX (20) leaving 5% of reflections in Free-R set.  Iterations of 
refinement using PHENIX (20) and CNS (22) and model building in Coot (21) lead to the 
current model, which consists of 173 residues (residues 12-184) with excellent geometrical 
characteristics (Table 1). 
The form II and Rv3066-ethidium crystals took the space groups P21212 and P3121, 
respectively.  These two structures were phased using the molecular replacement (MR) program 
PHASER (18) by using the form I structure as the search model.  Structural refinements were 
then performed using PHENIX
 
(20) and CNS
 
(22) (Table 1). 
The structure of Rv3066 
In the absence of inducer molecule, the Rv3066 regulator was crystallized in two 
different forms, I and II (Fig. S1).  The form I (SeMet) crystal structure was determined to a 
resolution of 2.3 Å (Table 1 and Fig. 1a).  The asymmetric unit contains a single homodimer, 
suggesting that this regulator is dimeric in nature.  Similar to LfrR (23), the left and right 
subunits of Rv3066 are asymmetrical.  The dimeric form I structure of Rv3066, indicating an all-
helical protein, is shown in Fig. 1b.  Superimposition of both subunits of Rv3066 gives rise to an 
overall root mean standard deviation of 1.3 Å calculated over the C atoms.   
The crystal structure of form II was refined to a resolution of 1.8 Å (Table 1).  Like form 
I, the structure of form II indicates that this protein is an asymmetric homodimer. 
Superimposition of the C atoms of the two subunits of form II results in an root mean standard 
deviation of 1.8 Å.  Surprisingly, the conformations of the structures of forms I and II are quite 
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distinct from each other, suggesting that these two structures probably represent two different 
transient states of the regulators.  Superimposition of the entire dimer of these two apo-Rv3066 
structures (forms I and II) provides an rms deviation of 3.0 Å (Fig. 2).  Overall, the architecture 
of these two Rv3066 structures are in good agreement with those of the homolog proteins TetR 
(24, 25), QacR (26, 27), CprB (28), EthR (29, 30), CmeR (31), AcrR (32), SmeT (33) and LfrR 
(23).  Each subunit of Rv3066 is composed of nine  helices (1-9 and 1-9, respectively) 
(Figs. 1b and 2) and can be divided into two motifs: an N-terminal DNA-binding domain and a 
C-terminal ligand-binding domain.  The helices of Rv3066 are designated numerically from the 
N-terminus as 1 (15-30), 2 (37-44), 3 (48-54), 4 (58-86), 5 (90-103), 6 (105-120), 7 
(122-143), 8 (145-165), and 9 (171-182).  In this arrangement, the smaller N-terminal domain 
includes helices 1 through 3 and the N-terminal end of 4 (residues 58-68), with 2 and 3 
forming a typical helix-turn-helix motif.  However, the larger C-terminal domain comprises the 
C-terminal end of helices 4 (residues 69-86) through 9, and helices 6, 8, and 9 are 
involved in the dimerization of the regulator.  The smaller N-terminal domain shares 
considerably high sequence and structural similarities with the TetR-family regulators, 
suggesting that Rv3066 belongs to the TetR family.  For example, residues 13-68 possess 20% 
amino acid identity and 68% homology to that of TetR (24). This N-terminal region also shows 
identities of 29% and 25%, and similarities of 62% and 63% to those of the M. smegmatis LfrR 
(23) and M. tuberculosis EthR repressors (30), respectively.  Protein sequence alignment of 
Rv3066 with the TetR-family members of other Mycobacterium species is shown in Fig. S2.  
This alignment suggests that Rv3066 is a member of the TetR family. 
 
 
19 
 
Conformational flexibility of the Rv3066 regulator 
Two distinct conformations of apo-Rv3066 were captured using crystallography, 
suggesting that this regulatory protein is quite flexible in nature.  A comparison of the N-terminal 
DNA-binding domains of the dimeric structures of forms I and II indicates that these two 
structures may depict two different transient states of the regulator.  Apparently, these two 
conformations are related by an 8
o
 rotational motion of the right subunit (helices 1-9) with 
respect to the left protomer (helices 1-9) is attributed to the difference (Fig. S2).  We can 
easily generate the form II conformation using the form I structure as a starting point and then 
following the rigid-body rotational trajectory based on the TLS (Translation/Libration/Screw) 
parameters.  The resulting final B-factors and overall R-factor/R-free of this form II dimeric 
Rv3066 structure are 24.0 Å
2
/22.9 Å
2
 (left/right subunits) and 21.4%/25.5%, respectively.  Thus, 
there is a chance that ligand binding triggers a rotational motion within the dimer of the 
regulator.  Presumably, this movement prohibits the binding of the dimeric regulator at its 
cognate DNA, which in turn releases the regulator from the promoter region and allows for the 
expression of the Mmr efflux pump. 
The C-terminal domain of the form II structure forms a large cavity, presumably creating 
a ligand-binding pocket of the regulator (Fig. S3). This cavity cannot be found in the form I 
structure.  Thus, it is likely that the form II crystal structure mimics the ligand-bound form of 
Rv3066.  The pocket, predominately formed by helices 5-8, opens horizontally from the side of 
each protomer. The total volume of these two binding pocket is about 540 Å
3
 (230 Å
3
 for the left 
subunit and 310 Å
3
 for the right subunit). Helices 4-6 of each subunit of form II make the 
entrance of the binding pocket, with residues V100, D104, and Y108 participating to form this 
entrance.   
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Structure of the Rv3066-ethidium complex 
 The crystal structure of the Rv3066-ethidium complex (Figs. 3 and S4) was refined to a 
resolution of 2.3 Å (Table 1), revealing that ethidium indeed binds within the ligand-binding 
pocket formed by the C-terminal domain.  Helices 5-8 contribute to form this pocket, and each 
subunit of Rv3066 is found to bind an ethidium molecule within the binding pocket.  
Superimposition of the dimeric Rv3066-ethidium structure to those of forms I and II apo-Rv3066 
result in overall root mean standard deviations of 3.4 and 1.9 Å, respectively.  
Although the conformations of the two subunits within the dimer are not identical, their 
ethidium binding modes are quite similar.  Both ethidium sites utilize the same set of amino 
acids to accommodate the binding, with a slight difference in the interaction distances.  The Fo - 
Fc electron density maps of the two bound ethidiums within the dimer are illustrated in Fig. 4a.  
Interestingly, the total volume of the two ligand-binding pocket has expanded to 929 Å
3
 (443 Å
3
 
for the left subunit and 486 Å
3
 for the right subunit) in the ethidium bound structure.   
 Each bound ethidium molecule is completely buried in the Rv3066 binding pocket.  The 
ligand binding pocket is found to be hydrophobic in nature.  Five aromatic residues, W80, Y101, 
Y115, W131 and F155, participate to make aromatic stacking interactions and hydrophobic 
contacts with the bound ethidium (Figs. 4b, 4c and S5).  Additionally, L76, T98, L111, and T159 
are involved to secure the binding through hydrophobic interaction.  Further, the N1 and N2 
amino group nitrogen of the phenanthridinium system of ethidium is hydrogen bonded to the side 
chain oxygen of T159 and S73 respectively (Table 2).  Additional hydrogen bonds have also 
been found between the N1 and N2 amino group nitrogens of the bound ethidium and the 
backbone oxygens of F155 and S73 to secure the binding (Table 2).  Furthermore, a negatively 
charged residue D156 participates to form the ligand binding site, and this residue is ~3.3 Å 
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away from the phenyl groups of the bound ethidium in each subunit of the dimer (Figs. 4b and 
S6).  
Docking of ligands into the multi-drug drug binding site 
To understand how Rv3066 binds different ligands, we used the program AutoDock Vina 
(34) to identify potential binding modes for a variety of drug molecules.  We first predicted an 
ethidium-binding site in Rv3066.  We found that the predicted bound ethidium molecule was 
completely overlapped with the bound ethidium identified from the crystal structure and their 
binding modes are nearly identical (Fig. S6), suggesting that AutoDock Vina is sufficiently 
precise for identification of potential drug-binding pockets.  When Vina was used to search for 
binding sites for different Rv3066 drugs, including acriflavine, proflavine, pyronin Y, safranin 
O, and thioridazine, it was found that all these drug molecules were bound within the ethidium-
binding site identified by X-ray crystallography (Fig. 9a and Table 3). 
Predicting the structure of DNA-bound form of Rv3066 
AutoDock Vina (34) was also used to generate a model of the Rv3066-DNA complex 
structure (Fig. 9b).  This model reveals that the two N-terminal domains of Rv3066 within the 
dimer are able to fit well into the two successive major grooves of the target DNA.  Extensive 
interactions between the regulator and DNA have also been found to stabilize this protein-DNA 
complex structure.  Specifically, T52 is found to make a contact with one base of IR1.  In 
addition, Y53 participates to interact directly with two different bases.  Additional stabilization 
of the complex comes from R15, H37 and R38, in which these residues make phosphate contacts 
with the DNA.    
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Discussion 
With the rise of resistant strains of TB, it is imperative that the mechanisms behind the 
proteins conferring resistance to these pathogens be understood. The two crystal structures of 
Rv3066—with and without the bound ethidium—provide direct information on the mechanism 
of this transcriptional regulator and how it controls the expression of the Mmr efflux pump, 
which confers resistance to several antimicrobial agents. Molecular docking of the N-terminal 
domains of apo-Rv3066 suggests that the two domains interact with two consecutive major 
grooves in DNA, preventing expression. 
Ethidium, by binding to Rv3066, triggers a series of cooperativity motions of the C-
terminal helices, including the horizontal shifts of helices 5, 6, and 7 toward the dimer 
interface, and an upward movement of helix 8 within one subunit of the regulator. These 
conformational changes initiate a rotational motion of the second subunit of Rv3066 with respect 
to the horizontal axis passing through the two ligand-binding pockets of the dimer (Figs. 3b, 5a 
and 5b), presumably making the relative orientation of the two N-terminal DNA-binding 
domains no longer compatible with the two consecutive major grooves of the operator B-DNA.  
The net result is that this dimeric regulator is released from the promoter, initiating the 
expression of the Mmr multidrug efflux pump. This induction mechanism is distinct from that of 
QacR (26, 27) and TetR (24, 25). A similar mechanism exists in the SimR (35) regulator where 
rigid body rotation within subunits of the dimer in relation to one another contributes to the 
induction.  
When comparing the form I and the ethidium-bound structures, the movements of helices 
5, 6 and 7 toward the dimer interface result in the formation of four new hydrogen bonds in 
the interface; they are between residues H120 and R109’, and R121, and Q113’. The backbone 
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oxygens of R129 and I169’, and T165 and R129’ form the other two hydrogen bonds in the 
interface. They are presumed to stabilize the ligand bound form of the Rv3066 dimer. 
In addition to the C-terminal helices’ movements, residues located within the binding site 
also readjusted their positions to accommodate the binding of ethidium. Y155 shifts upward by 
2.4 Å, presumably to make an interaction with the phenyl groups of the ethidium molecule. 
W131 shifts upward by 2.3 Å to make aromatic stacking interactions with the three-ring system 
of the phenanthridinium group of ethidium. Many multidrug binding proteins accommodate for 
different ligands by having flexibility in their binding regions. This can be seen in the Rv3066 
binding pocket, further demonstrating that Rv3066 and the Mmr proteins can recognize multiple 
antimicrobial agents. 
 We used the program AutoDock Vina (34) to study how Rv3066 can interact with 
other possible ligands. The docking study shows that the large cavity of the multi-drug binding 
site of each Rv3066 monomer can accommodate many other drugs, such as acriflavine, 
proflavine, pyronin Y, safranin O, and thioridazine.  In each case, the bound drug was 
completely buried in the Rv3066 molecule, and strong interaction was observed between the 
bound drug and the regulator (Table 3).  The dockings suggested that all these ligands are bound 
in the same multi-drug binding site with a similar binding mode, suggesting that the process of 
induction by these drugs is similar. However, due to the method used in this docking, we cannot 
rule out other possible interactions within the binding pocket.  
Another distinguishing feature of multidrug-binding proteins (that bind cationic drugs) is 
the presence of buried acidic glutamates or aspartates in the ligand binding regions. This has 
been seen in the structures of QacR-ligand complexes (26), within the ligand-binding pocket of 
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the AcrR efflux regulator (32), and in the TetR-family of regulators (31, 36). For TetR, it is the 
histidines or lysines that are critical. 
 In Rv3066, fluorescence polarization and mutagenesis studies by Bolla indicate 
that D156 is critical for ethidium binding. Even though it does not participate in hydrogen-
binding with ethidium , it, along with N112, is responsible for forming hydrogen bonds with the 
aromatic residues Y101, Y115, and W131 (Fig. 4b). W80 and these three residues form an 
aromatic cage-like binding pocket to position the ethidium ligand (Fig. S7).  The importance of 
the cage-like arrangement of these aromatic residues to bind ethidium is further demonstrated 
using mutagenesis and fluorescence polarization studies, in which the W80-W131 double mutant 
has been found to bind ethidium 20 times weaker than the wild-type Rv3066.  
Each Rv3066 dimer binds two drug molecules—one in each subunit. Gel filtration done 
by Bolla confirmed that the Rv3066-IR1 complex should be in the form of 1:1 dimeric Rv3066-
to-DNA molar ratio. The structures of the Rv3066 regulator both in the absence and presence of 
bound ethidium, together with the experimental data from support the role of Rv3066 in 
regulating the expression level of the multidrug efflux pump Mmr in M. tuberculosis. 
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Fig. 1a 
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Fig. 1b 
 
Figure 1.  Stereo view of the experimental density map and ribbon diagram of the crystal 
structure of Rv3066. (a) Representative section of electron density in the vicinity of helices 5 
and 8. The solvent-flattened electron density (40-2.3 Å) is contoured at 1 and superimposed 
with the final refined model (magenta, carbon; red, oxygen; blue nitrogen). (b) Ribbon diagram 
of the Rv3066 dimer. Helices 1-9 (left subunit) and 1-9 (right subunit) are labeled.  The 
Figure was prepared using PyMOL (http://www.pymol.sourceforge.net). 
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Figure 2.  Structural comparison of forms I and II of the Rv3066 regulator.  This is a 
superimposition of the dimeric structures of forms I and II (orange, form I; blue, form II).  
Helices 1-9 (left subunit) and 1-9 (right subunit) are labeled.  The arrow indicates a 
change in orientation of the right subunit of form II when compared with the structure of form I.  
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Fig. 3a 
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Fig. 3b. 
Figure 3.  Crystal structure of the Rv3066-ethidium complex.  (a) Ribbon diagram of the 
Rv3066-ethidium complex.  The bound ethidiums are shown as sticks (magenta, carbon; blue, 
nitrogen).  (b) Structural comparison of form I and Rv3066-ethidium.  This is a superimposition 
of the dimeric structures of form I (orange) and Rv3066-ethidium (green).  The bound ethidiums 
are in yellow sticks.  Helices 1-9 (left subunit) and 1-9 (right subunit) are labeled.  The 
arrow indicates a change in orientation of the right subunit of dimeric Rv3066-ethidium when 
compared with the form I structure.  This conformational change can be interpreted as a 
rotational motion of the right subunit of Rv3066 with respect to the horizontal axis passing 
through the two ligand-binding pockets of the dimer upon ethidium binding.  
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Fig. 4a. 
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Fig. 4b.  
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Fig. 4c.  
 
 
Figure 4.  Electron density maps and the ethidium binding site.  (a) Stereo view of the Fo - Fc 
electron density map of the bound ethidium in the left subunit of dimeric Rv3066 (the orientation 
corresponds to Fig. 3a).  The bound ethidium is shown as a stick model (magenta, carbon; blue, 
nitrogen).  The Fo - Fc map is contoured at 3.0  (blue mesh).  The surrounding secondary 
structural elements are shown as yellow ribbons.  (b) The ethidium-binding site of the left 
subunit of the dimeric Rv3066-ethidium complex.  Residues involved in ethidium binding are in 
green sticks.  The bound ethidium is shown as yellow sticks.  Dotted lines depict the hydrogen 
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bonds.  (c) Superimposition of the ligand-binding pocket before and after ethidium binding.  
Residues involved in ethidium binding are shown as sticks (orange, form I; green, Rv3066-
ethidium). 
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Fig. 5a. 
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Fig. 5b. 
 
 
Figure 5.  Docking of drugs and DNA onto the structure of Rv3066.  (a) This is a composite 
figure showing the locations of the predicted bound ligands in the ligand-binding pocket.  The 
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ligands shown in stick models are ethidium (orange), acriflavine (red), proflavine (cyan), pyronin 
Y (blue), safranin O (yellow) and thioridazine (magenta).  (b) Speculative model of Rv3066 in 
its DNA-bound form.  It is expected that the Rv3066-IR1 complex is formed by binding a dimer 
of Rv3066 (green) to a double-stranded IR1 (orange). 
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Fig. S1a.
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Fig. S1b. 
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Fig. S1c. 
 
  
Fig. S1.  Packing diagrams of the Rv3066 crystals.  (a) Packing diagram of the form I crystal 
viewed along the c axis.  The two subunits of one of the dimeric Rv3066 are colored green and 
magenta.  The rest of the other dimers are colored gray.  (b) Packing diagram of the form I 
crystal viewed along the c axis.  The two subunits of one of the dimeric Rv3066 are colored 
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green and magenta.  The rest of the other dimers are colored gray.  (c) Packing diagram of the 
form I crystal viewed along the c axis.  The two subunits of one of the dimeric Rv3066 are 
colored blue and magenta.  The rest of the other dimers are colored gray. 
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Fig. S2.  Side view of the superimposition of the dimeric structures of forms I and II (orange, 
form I; blue, form II).  This view depicts an 8
o
 rigid body rotation of the right subunit (1-9) 
of form II with respect to that of form I.  
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Fig. S3.  The hydrophobic binding pocket of form II of apo-Rv3066.  This pocket was calculated 
using the program CAVER (http://loschmidt.chemi.muni.cz/caver).  The binding tunnel on each 
subunit of Rv3066 is colored gray.  
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Fig. S4a. 
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Fig. S4b. 
  
  
49 
 
 
  
Fig. S4c. 
 
 
Fig. S4.  Structural comparison of form I and Rv3066-ethidium.  (a) Side view of the 
superimposition of the dimeric structures of form I and Rv3066-ethidium (orange, form I; green, 
ethidium bound).  This view depicts a 10
o
 rigid body rotation of the right subunit (1-9) of 
Rv3066-ethidium with respect to that of form I.  (b) Superimposition of the N-terminal domains 
of form I and Rv3066-ethidium.  The secondary structural elements are shown as ribbons 
(orange, form I; green, Rv3066-ethidium).  (c) A schematic representation illustrating the rigid-
body rotation of the subunits relative to one another.  This side view demonstrates a 10
o
 rotation 
of the right subunit of Rv3066 with respect to the left one after ethidium binding. 
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Fig. S5.  The ethidium binding pocket and electron density map of the right subunit of dimeric 
Rv3066.  This 2Fo - Fc electron density map is contoured at 1.5  (gray mesh).  The figure 
indicates that the aromatic residues W80, Y101, Y115 and W131 (green) form a cage-like 
binding site to house the bound ethidium (orange), suggesting aromatic stacking interactions 
govern drug recognition of the regulator.  The hydrogen bond distances between D156 and 
Y115, D156 and W131, and N112 and Y101 are 2.7, 2.7, and 2.7 Å, respectively.   
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Fig. S6 .  Binding site prediction for Rv3066.  The bound ethidiums from the crystal structure 
and from prediction are colored green and orange, respectively. 
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Table 1.  Data collection, phasing and structural refinement statistics 
 
  
 Form I Form II Rv3066-ethidium 
Data Collection    
   Wavelength (Å) 0.978 0.978 0.978 
   Space group P21212 P21212 P3121 
   Cell constants(Å) a=78.7, b=118.9, 
c=42.1 
a=91.4, b=119.9, 
c=30.9 
a=99.1, b=99.1, 
c=66.5 
   Resolution(Å) 2.32 (40.00-2.32) 1.83 (40.00-1.83) 2.30 (40.0-2.30) 
   Completeness (%) 99.9 (99.9) 96.0 (98.4) 100.0 (99.6) 
   Total no. of        
     reflections 
556,100 524,555 670,642 
   No. of unique  
     reflections 
17,973 31,246 17,079 
   Redundancy 2.4 (2.5) 2.7 (2.9) 3.1 (3.2) 
   Rmerge (%) 36.4 (7.7) 39.8 (4.9) 36.4 (5.7) 
   (I/σ(I)) 2.17 (11.65) 2.08 (23.47) 2.94 (26.33) 
Phasing    
   Selenium atom sites 2   
   Resolution range of  
     data used (Å) 
40.00-2.32   
   Figure of merit      
     (acentric/centric) 
56.1/42.4   
Refinement    
   Rwork (%) 20.28 20.40 20.59 
   Rfree (%) 27.06 24.71 26.16 
   B-factors    
      Overall (Å2) 38.5 24.6 48.0 
      Protein chain A/B   
        (Å2) 
39.0/36.9 25.8/23.3 45.8/50.3 
      Ligand chain A/B   
        (Å2) 
- - 37.0/36.6 
      Water   (Å) 39.2 29.3 41.1 
   No. of atoms in    
      protein chain A/B 
 
1,329/1,329 
 
1,321/1,321 
 
1,322/1,329 
   No. of ligands 0 0 2 
   No. of waters 77 67 64 
Rms deviations    
   Bond angles (°) 1.1 0.9 1.0 
   Bond length (Å) 0.008 0.007 0.008 
Ramachandran analysis    
   Most favored regions  
     (%) 
94.9 94.3 94.2 
   Allowed regions (%) 5.1 5.7 5.8 
   Generously allowed  
     regions (%) 
0.0 0.0 0.0 
   Disallowed regions  
     (%) 
0.0 0.0 0.0 
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Table 2. Rv3066-ethidium contacts. Contacts within 4.8 Å of the bound ethidiums are listed. 
 
 
 Distance (Å) 
Residue-ligand contacts A chain B chain 
S73 2.7
a 
2.7
a 
S73 (backbone oxygen) 2.9
a 
2.9
a 
L76 3.1 3.6 
W80 3.6 3.7 
T98 3.5 3.5 
Y101 3.4 3.5 
L111 4.6 4.3 
N112 3.5 3.2 
Y115 3.3 3.4 
W131 3.0 3.0 
F155 3.9 3.8 
F155 (backbone oxygen) 2.9
a 
2.7
a 
D156 3.3 3.3 
T159 2.9
a 
2.7
a 
a 
Hydrogen bond distance 
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Table 3.  Docking of ligands and DNA onto the Rv3066 regulator 
 
 Binding affinity (kcal/mol) 
Rv3066-ethidium -12.7 
Rv3066-acriflavine -11.6 
Rv3066-proflavine -10.8 
Rv3066-pyronin Y -7.3 
Rv3066-safranin O -8.9 
Rv3066-thioridazine -8.3 
Rv3066-IR1 -10.9 
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Abstract 
Gram-negative bacteria expel various toxic chemicals via tripartite efflux pumps 
belonging to the resistance-nodulation-cell division (RND) superfamily.  These pumps span both 
the inner and outer membranes of the cell.  The three components of these tripartite systems are 
an inner membrane, substrate-binding transporter (or pump); a periplasmic membrane fusion 
protein (or adaptor); and an outer membrane-anchored channel.  These three efflux proteins 
interact in the periplasmic space to form the three-part complex.  One such efflux system, 
CusCBA, is responsible for extruding Cu(I) and Ag(I) ions, which are biocides.  We previously 
presented the crystal structures of both the inner membrane transporter CusA and membrane 
fusion protein CusB of the CusCBA tripartite efflux system from Escherichia coli.  We also 
described the co-crystal structure of the CusBA adaptor-transporter, revealing that the trimeric 
CusA efflux pump assembles with six CusB protein molecules to form the complex CusB6-
CusA3.  Recently, we reported three different conformers of the crystal structures of CusBA-
Cu(I), suggesting a mechanism on how Cu(I) binding initiates a sequence of conformational 
transitions in the transport cycle.  Herein, we summarize the structural information of these 
efflux proteins, and present the accumulated evidence that this efflux system utilizes conserved 
methionine as well as charged amino acids to bind and export Cu(I) and Ag(I) ions.  
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Introduction 
Efflux pumps of the RND superfamily are integral membrane proteins that derive energy 
from the proton motive force (PMF).  These efflux systems are widely distributed and found 
ubiquitously in bacteria, archaea and eukaryotes.  In Gram-negative bacteria, which contain two 
membrane layers in the cell envelope, these export systems play major roles in the intrinsic and 
acquired tolerance of antibiotics and toxic compounds.  They assemble as tripartite efflux pumps, 
spanning both the inner and outer membranes, to extrude antimicrobial and toxic compounds out 
of the cell (Figure 1). 
The Gram-negative bacterium E. coli harbors seven different RND efflux transporters 
(Table 1).  These seven transporters can be categorized into two distinct sub-families, the 
hydrophobic and amphiphilic efflux RND (HAE-RND) and heavy-metal efflux RND (HME-
RND) families (Tseng et al., 1999; Nies, 2003). Six of these transporters, such as AcrB 
(Zgurskaya and Nikaido, 1999; Nishino and Yamaguchi, 2001; Murakami et al., 2002; Yu et al., 
2003; Yu et al., 2005; Murakami et al., 2006; Seeger et al., 2006; Su et al., 2006; Sennhauser et 
al., 2007; Das et al., 2007; Törnroth-Horsefield et al., 2007), AcrD (Rosenberg et al., 2000; 
Nishino and Yamaguchi, 2001; Aires and Nikaido, 2005), AcrF (Ma et al., 1993; Nishino and 
Yamaguchi, 2001; Lau and Zgurskaya, 2005), MdtB (Nishino and Yamaguchi, 2001; Baranova 
and Nikaido, 2002; Nagakubo et al., 2002), MdtC (Nishino and Yamaguchi, 2001; Baranova and 
Nikaido, 2002; Nagakubo et al., 2002) and YhiV (Nishino and Yamaguchi, 2001; Kobayashi, 
2001; Bohnert et al., 2007), are multidrug efflux pumps, which belong to the HAE-RND protein 
family (Tseng et al., 1999).  In addition to these multidrug efflux pumps, E. coli contains one 
HME-RND efflux transporter, CusA, which specifically recognizes and confers resistance to 
Ag(I) and Cu(I) ions (Franke et al., 2001; Franke et al., 2003). 
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The CusA transporter operates with a periplasmic membrane fusion protein (MFP or 
adaptor), CusB, and an outer membrane channel (OMC), CusC, to form a functional protein 
complex.  CusA is a large PMF-dependent inner membrane RND efflux pump comprised of 
1,047 amino acids (Franke et al., 2001; Franke et al., 2003).  CusC is a 440-residue protein that 
forms an OMC (Franke et al., 2001; Franke et al., 2003).  The MFP CusB is a 379-amino acid 
polypeptide, contacting both the inner membrane CusA and outer membrane CusC efflux 
proteins (Franke et al., 2001; Franke et al., 2003).  The resulting CusCBA tripartite efflux system 
spans the entire cell envelope and confers resistance to Cu(I) and Ag(I) by exporting these metal 
ions directly out of the cell.  Heavy-metal efflux by the CusCBA complex is driven by proton 
import, and this process is catalyzed through the inner membrane transporter CusA. 
Among those transporters belonging to the RND superfamily, the structural and 
functional relationships of the HAE-RND pumps have been elucidated.  Currently, two crystal 
structures of the HAE-RND-type efflux pumps, the E. coli AcrB (Murakami et al., 2002; Yu et 
al., 2003; Yu et al., 2005; Murakami et al., 2006; Seeger et al., 2006; Su et al., 2006; Sennhauser 
et al., 2007; Das et al., 2007; Törnroth-Horsefield et al., 2007) and Pseudomonas aeruginosa 
MexB (Sennhauser, 2009) multidrug transporters, have been determined.  Their structures 
suggest that both AcrB and MexB span the entire width of the inner membrane and protrude 
approximately 70 Å into the periplasm.  Along with the models of these two HAE-RND 
transporters, the crystal structures of the other components of these tripartite complex systems 
have also been resolved.  These include the OMCs, E. coli TolC (Koronakis et al., 2000) and P. 
aeruginosa OprM (Akama et al., 2004), as well as the MFPs, E. coli AcrA (Mikolosko, 2006) 
and P. aeruginosa MexA (Higgins et al., 2004; Akama et al., 2004; Symmons et al., 2009). 
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Unlike the HAE-RND family, members of the HME-RND family are highly substrate-
specific.  To date, E. coli CusA is the only HME-RND transporter that has available crystal 
structures. These structures immediately suggested a mechanism on how this efflux transporter 
specifically recognizes monovalent Cu(I) and Ag(I) ions.  In addition, the crystal structures of 
individual components, the MFP CusB and OMC CusC, within the CusCBA tripartite efflux 
system have been determined.  Recently, the X-ray structure of the CusBA efflux complex has 
also been described.  This is the first co-crystal structure of an adaptor-transporter efflux 
complex in any efflux pump family.  The structure indicates that the complete assembly of the 
CusCBA tripartite efflux complex should be in the form of CusC3-CusB6-CusA3 that spans both 
the inner and outer membranes of E. coli and extrudes Cu(I) and Ag(I) ions (Su et al., 2011).  In 
this chapter, we summarize the structural information of these efflux proteins.  Genetic analysis 
and transport assay strongly indicate that the conserved charged residues as well as the 
methionine pairs and clusters of CusA are essential for extruding metal ions out of the bacterial 
cell.  Based on the current findings of the CusCBA efflux system, we put forward our opinion on 
how these protein machines facilitate metal transport.  
The CusB Membrane Fusion Protein 
Crystal structure of the CusB membrane fusion protein 
The crystal structure of CusB (pdb code: 3H9I), comprising approximately 80% of the 
protein (residues 89-385), was determined to a resolution of 3.40 Å (Su et al., 2009).  This 
structure has allowed us to reveal novel structural features that are not found in other known 
MFP structures.  The crystal structure indicated that the asymmetric unit of the crystal consists of 
two protomers.  These two CusB molecules were found to interact with each other.  However, 
the functional oligomerization state of this protein was still not clear at that time.  Each CusB 
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molecule is folded into an elongated polypeptide, ~120 Å long and ~40 Å wide, and can be 
divided into four different domains (Figure 2).  The first three domains of the protein are mostly 
-strands.  The fourth domain, however, forms an all -helical domain, which is folded into a 
three-helix bundle secondary structure. 
The first -domain (Domain 1) of CusB is formed by the N and C-terminal ends of the 
polypeptide (residues 89-102 and 324-385).  This domain is located directly above the outer-
leaflet of the inner membrane.  By coupling cross-linking with mass spectrometry, it has been 
suggested that this domain specifically interacts with the periplasmic domain of the CusA efflux 
pump (Su et al., 2009). Overall, Domain 1 is a -barrel domain, consisting of six -strands, with 
the N-terminal end forming one of the -strands while the C-terminus of the protein constitutes 
the remaining five strands (Figure 1).  
The second -domain (Domain 2) of CusB is formed by residues 105-115 and 243-320.  
This domain comprises six -strands and one short -helix.  Again, the N-terminal residues form 
one of the -strands that is incorporated into this domain.  The C-terminal residues contribute a 
-strand, an -helix and four anti-parallel -sheets.  In an asymmetric unit of the crystal, the two 
molecules of CusB contact one another in an anti-parallel fashion, with Domains 1 and 2 of one 
molecule interact closely with Domains 2 and 1 of the other molecule, respectively (Su et al., 
2009). It was later found that these two domains are important for the oligomerization of this 
CusB adaptor. 
Domain 3 is another globular -domain adjacent to the second domain of CusB.  This 
domain consists of residues 121-154 and 207-239, with a majority of these residues folding into 
eight -strands. 
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Perhaps the most interesting motif appears to be in the fourth domain (Domain 4) of 
CusB.  This region, comprising residues 156-205, forms an all-helical domain.  Surprisingly, this 
domain is folded into an anti-parallel, three-helix bundle (Su et al., 2009). This structural feature, 
not found in other known protein structures in the MFP family, highlights the uniqueness of the 
CusB protein.  The helix bundle creates an ~27 Å long helix-turn-helix-turn-helix secondary 
structure, making it at least 20 Å shorter than the two-helical hairpin domains of MexA (Higgins 
et al., 2004; Akama et al., 2004; Symmons et al., 2009) and AcrA (Mikolosko et al., 2006). To 
date, CusB is the only periplasmic protein in the MFP family that possesses this three-helical 
domain instead of a two-helical hairpin motif. 
The crystal structure of CusB represents the first structure of any MFP that is associated 
with an HME-RND-type transporter.  Among all known structures of the MFP family, including 
AcrA (Mikolosko et al., 2006) and MacA (Yum et al., 2009), the CusB (Su et al., 2009), MexA 
(Symmons et al., 2009) and ZneB (De Angelis et al., 2010) proteins exhibit the most complete 
three-dimensional structures.  Like MexA and ZneB, the structure of CusB revealed that this 
MFP consists of four major domains, including three -strand domains and one -helical 
domain.  However, CusB is folded into a distinct secondary structure when compared with the 
other available MFP structures.  This distinct structural feature may underscore the unique 
functionality of CusB in the MFP family. 
Cross-linking and mass spectrometry 
To determine how CusB interacts with the CusA efflux pump and the relative orientation 
of CusB in the efflux complex, the purified CusA and CusB proteins were cross-linked using the 
lysine-lysine cross-linker disuccinimidyl suberate.  The resulting product was then digested with 
trypsin and examined using LC-MS/MS.  Analysis of the mass spectral data suggests that the 
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lysine residue of the polypeptide IDPTQTQNLGVKTATVTR originating from the N-terminal 
residues (84-101) of CusB directly interacts with the lysine residue of the peptide 
SGKHDLADLR (residues 148-157 of CusA), which is supposed to form part of the N-terminal 
periplasmic loop of the CusA efflux pump (Su et al., 2009). Together with the crystal structure of 
CusB and the mass spectrometric data, it was suggested that Domain 1, formed by the N and C-
terminal ends, of CusB should directly interact with the periplasmic domain of the CusA 
transporter.  This result is indeed in good agreement with the cross-linking study that the N and 
C-termini of AcrA specifically interact with the periplasmic domain of AcrB (Symmons et al., 
2009)
.
   
The CusA Heavy-Metal Efflux Pump 
Crystal structure of the CusA heavy-metal efflux pump 
The crystal structure of the CusA efflux pump (Long et al., 2010) was resolved to a 
resolution of 3.52 Å, with 98% of the residues (residues 5-504 and 516-1040) included in the 
final model (pdb code: 3K07) (Figure 3).  Overall, the crystal structure of CusA is quite distinct 
from those of the HAE-RND pumps AcrB and MexB.  Superimposition of the structure of CusA 
with the structure of AcrB (Murakami et al., 2002) results in a high RMSD of 11.4 Å for 1,003 
C atoms, suggesting highly significant differences between these two transporters.  CusA exists 
as a homotrimer, and each subunit of CusA consists of 12 transmembrane helices (TM1-TM12) 
and a large periplasmic domain formed by two periplasmic loops between TM1 and TM2, and 
TM7 and TM8, respectively (Figure 3A).  In the transmembrane region, the relative locations of 
TM1-TM6 are related to those of TM7-TM12 by pseudo-twofold symmetry.  These TM helices 
are arranged in such a way that TM4 and TM10 form the center of the core and are surrounded 
by the other TM helices.  Unlike AcrB and MexB, four helices, TM4, TM5, TM10 and TM11, 
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extend into the cytoplasm to form the cytoplasmic domain of the pump.  Two other helices, TM2 
and TM8, protrude into the periplasm and contribute part of the periplasmic domain.  It is 
important to note that TM2, TM4 and TM5 of the N-terminal half correspond to TM8, TM10 and 
TM11 of the C-terminal half, respectively, in the pseudo-twofold symmetry.  
Like AcrB and MexB, the periplasmic domain of CusA can be divided into six sub-
domains: PN1, PN2, PC1, PC2, DN and DC (Figure 3B).  Sub-domains PN1, PN2, PC1 and PC2 
form the pore domain, with PN1 making up the central pore and stabilizing the trimeric 
organization.  Sub-domains DN and DC, however, contribute to form the docking domain, 
presumed to be interacting with the outer membrane channel CusC.  The trimeric CusA structure 
suggests that sub-domains PN2, PC1 and PC2 are located at the outermost core of the 
periplasmic domain, facing the periplasm.  In AcrB, sub-domains PC1 and PC2 form a large 
external cleft and create the entrance for drug molecules from the periplasm.  However, the apo-
CusA structure shows that the gap between PC1 and PC2 is completely closed (Figure 3B).  As 
mentioned above, in vitro cross-linking coupled with mass spectrometry suggested that the 
polypeptide SGKHDLADLR (residues 148-157 of CusA) should interact with the N-terminus of 
the MFP CusB.  This polypeptide was found to be located at sub-domains PN2 of CusA in the 
crystal structure. 
Perhaps the most interesting secondary structural feature appears in the cleft region of the 
periplasmic domain.  Residues located on the left side of the wall, formed by one -helix 
(residues 690-706) and three -sheets (residues 681-687, 711-716 and 821-827), are found to tilt 
into the cleft to close the opening.  Surprisingly, residues 665-675, located at the bottom of the 
cleft, form an -helix.  This structural feature, not found in AcrB and MexB, likely governs the 
specificity of the CusA pump.  The -helix orients horizontally and roughly divides the 
64 
 
transmembrane and periplasmic domains into two compartments.  Located just above this 
horizontal helix are three proximal methionine residues, M573, M623 and M672, presumably 
creating a three-methionine specific binding site for Cu(I) and Ag(I) ions (Zhou and Thiele, 
2001; Jiang et al., 2005). Notably, M672 is also one of the residues within the horizontal helix.  
Site-directed mutagenesis had suggested that these three methionine residues are essential for 
mediating copper resistance (Franke et al., 2003). Indeed, a strong peak at the copper edge was 
observed at the center of these three methionines in our CusA-Cu(I) crystal derivative, indicating 
the binding of a Cu(I) ion in a three-sulfur binding site. 
Crystal structures of the CusA-Cu(I) and CusA-Ag(I) complexes 
The copper-edge wavelength (1.3779 Å) was used to collect the X-ray diffraction data of 
the CusA-Cu(I) crystal.  These data have allowed us to identify the location of the bound Cu(I).  
Intriguingly, the overall structure of the CusA-Cu(I) complex (pdb code: 3KSS) (Long et al., 
2010) is quite distinct from that of apo-CusA (Figure 4).  Superimposition of these two structures 
gives an overall RMSD of 3.9 Å (for 1,006 C atoms).  As mentioned above, the bound Cu(I) 
ion was found to coordinate residues M573, M623 and M672.  These three methionines 
specifically form a typical three-methionine coordination site for binding Cu(I)/Ag(I) (Zhou and 
Thiele, 2001; Jiang et al., 2005). Binding of Cu(I) initiates significant conformational changes in 
the periplasmic as well as the transmembrane domains of CusA. Perhaps, the most noticeable 
difference between the apo and ion-bound structures appears in the PC2 region (Figure 4A and 
B).  Cu(I) binding leads to a 30
o
 swing of the entire PC2 sub-domain.  This motion shifts PC2 
away from the PC1 sub-domain.  The hinge for this rotational movement appears to be at the 
junction between sub-domains PC2 and DC with residues G721 and P810 forming the hinge.  As 
a consequence, the gap between PC1 and PC2 appears to open up after binding this metal ion 
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(Figure 4A and B).  This gap presumably creates an entrance for metal ions from the periplasmic 
space.  The horizontal helix, residues 665-675, located inside the cleft also makes a substantial 
movement.  The C-terminal end of this helix is found to tilt upward by 21
o
 in the Cu(I)-bound 
structure with respect to the apo form (Figure 4C).  This tilting motion allows M672 to move 
closer to M573 and M623 to complete the three-methionine coordination site.  Coupled with this 
movement, TM8 also shifts in position to a more vertical orientation while retaining its -helical 
structure.  Overall, the N-terminal end of TM8 is found to shift away from the core by 10 Å after 
Cu(I) binding. 
For the CusA-Ag(I) complex (pdb code: 3KSO) (Long et al., 2010), an anomalous 
difference Fourier peak was found at the center of residues M573, M623 and M672, indicating 
that the bound Ag
+
 ion is coordinated by these three methionines (Figure 4D).  The overall 
conformational changes triggered by Cu(I) and by Ag(I) binding are nearly identical.  
Superimposition of the CusA-Cu(I) and CusA-Ag(I) structures gives an overall RMSD of 1.0 Å 
(for 1,021 Cs).  Based on the crystal structures, the horizontal helix in the cleft directly interacts 
with the N-terminal end of TM8.  The movement of TM8 may relate directly to transmembrane 
signaling and could initiate the translocation of a proton across the membrane.  Indeed, in the 
AcrB pump, there is evidence that proton translocation is coupled to the conformational change 
in TM8 (Su et al., 2006; Sennhauser et al., 2007). The change in conformation takes place in 
TM8 by reeling in some random coil residues to extend the  helix (Sennhauser et al., 2007). In 
addition, when individual residues of the proton-relay network was changed to alanine, 
disrupting the hydrogen bonds in the system, it was reported that TM8 of AcrB becomes longer 
and extends into the periplasmic domain (Su et al., 2006). In contrast to AcrB, the helical 
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structure of the N-terminus of TM8 in CusA is retained after metal binding.  Instead, the N-
terminal end of TM8 moves outward, together with the movement of the PC2 sub-domain. 
 
Intriguingly, it appears that the binding of Cu(I) or Ag(I) also triggers significant 
conformational changes in the other transmembrane helices of  the pump.  In addition to the 
movement of TM8, all other transmembrane helices except TM2 shift horizontally by as much as 
4 Å, mimicking the motion of TM8.  Further, TM1, TM3 and TM6 readjust in an approximately 
3 Å upward shift with respect to the inner membrane surface.  The net result is that all three of 
these transmembrane helices move towards the periplasm by one turn.  Mutagenesis studies of 
the transmembrane domain of CusA indicated the conserved charged residue D405 of TM4 to be 
essential for transporter function (Franke et al., 2003). Based on the crystal structure, this acidic 
residue interacts with E939 and K984.  It is possible that these three charged residues participate 
in forming the proton-relay network in the transmembrane region of the pump.  
Coupled with the above conformational changes, the sub-domain PN1 at the periplasmic 
domain was also found to undergo substantial movement.  Overall, PN1 also shifts upward by 3 
Å.  This moves the central pore helix upward by one turn upon metal binding.  It should be noted 
that the binding of metal ions does not significantly affect the conformation of the sub-domains 
DN, DC, PN2 or the transmembrane helix TM2.   
The methionine-residue ion relay network 
The full-length CusA includes 34 methionine residues with 18 of them located in the 
transmembrane domain.  Of the 18 methionines, six are paired up to form three distinct 
methionine pairs.  These methionine pairs are M410 of TM4 and M501 of TM6; M403 of TM4 
and M486 of TM6; and M391 of TM4 and M1009 of TM12 (Figure 5).  It is known that copper 
tolerance proteins, such as CusF (Loftin et al., 2007; Xue et al., 2008), CueR (Changela et al., 
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2003) and Atx1(Arnesano, 2001), frequently utilize two-methionine or two-cysteine binding 
pockets to carry their Cu(I)/Ag(I) cargos.  Thus, these methionine pairs could potentially form 
binding sites for Ag(I) and Cu(I) in the transmembrane region of the pump.  If this is the case, 
then CusA could transport these metal ions from the cytoplasm along these methionine pairs.  In 
the periplasmic domain of CusA, we have found another methionine pair (M271-M755) in 
addition to the three-methionine metal binding site (Figure 5).  In view of the crystal structures, 
these five methionine pairs/clusters are deemed to be important for binding and transport of 
metal ions. 
We then determined whether the CusA protomer forms a channel by using the program 
CAVER (http://loschmidt.chemi.muni.cz/caver) and found that each protomer of CusA forms a 
channel spanning the entire transmembrane region up to the bottom of the periplasmic funnel 
(Figure 5).  Intriguingly, the channel includes four methionine pairs, three (M410-M501, M403-
M486, M391-M1009) from the transmembrane region and one (M271-M755) from the 
periplasmic domain, as well as the three-methionine binding site formed by M573, M623 and 
M672 (Figure 5).  Taken together, these five methionine pairs/clusters are likely to form a relay 
network facilitating metal ion transport.  Remarkably, this channel spans almost the entire length 
of each protomer, from the transmembrane domain through to the bottom of the periplasmic 
funnel region, and is likely to represent a real path for transporting the metal ion from both the 
cytoplasm and periplasm to the periplasmic funnel for extrusion. 
In vivo metal susceptibility assay 
We made an E. coli knockout strain BL21(DE3)∆cueO∆cusA that lacks both cueO and 
cusA.  The cueO gene encodes a putative multicopper oxidase, CueO, which is also involved in 
copper homeostasis (Grass and Rensing, 2001).  We mutated M573, M623 and M672, which are 
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members of the binding site triad inside the cleft of the periplasmic domain, into isoleucines 
(M573I, M623I and M672I).  We then expressed these three mutant transporters in 
BL21(DE3)∆cueO∆cusA, and tested their ability to confer copper and silver resistance in vivo.  
We found that the CusA mutants, M573I, M623I and M672I are unable to relieve the copper or 
silver sensitivity of strain BL21(DE3)∆cueO∆cusA, thus agreeing well with the work of Franke 
et al. (Franke et al, 2003) in which M573, M623 and M672 were shown to be essential for the 
function of CusA. 
We mutated M410 into an isoleucine (M410I) to disrupt the pair formed by M410 and 
M501 at the bottom of the transmembrane. We also replaced M486 and M391, which pair with 
M403 and M1009, with isoleucines (M486I and M391I).  Expression of these three mutants in 
BL21(DE3)∆cueO∆cusA showed a significant decrease in the level of copper and silver 
tolerances when compared with cells expressing wild-type CusA. In addition, we introduced 
M755I in the periplasmic domain.  Again, when expressed in BL21(DE3)∆cueO∆cusA, this 
mutant transporter (M755I) showed a decrease in copper/silver tolerance in comparison with 
cells harboring the wild-type transporter. Together, these results strongly support the hypothesis 
that these methionine pairs/clusters engage in the methionine-residue ion relay channel. 
Based on the crystal structure of CusA, it is expected that the charged residues D405, 
E939 and K984 are important for the proton-relay network of the pump, so they were replaced 
with alanines (D405A, E939A and K984A) to disrupt the hydrogen-bonded network.  Indeed, 
cells expressing this mutant were unable to tolerate copper and silver, demonstrating that these 
three charged residues are essential for the transporter’s functioning. 
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In vitro metal transport assay 
To investigate whether CusA can transport metal ions from the cytoplasm, we 
reconstituted the purified CusA protein into liposomes containing the fluorescent indicator Phen 
Green SK in the intravesicular space.  The intravesicular and extravesicular pHs of these 
proteoliposomes were 6.6 and 7.0, respectively.  We then determined whether these 
proteoliposomes can capture metal ions from the extravesicular medium with a stopped-flow 
transport assay.  (The charged metal ions are unlikely to diffuse spontaneously across membrane 
bilayers.)  When Ag
+
 ions were added into the extravesicular medium, we detected the 
quenching of the fluorescence signal, suggesting the uptake of Ag
+
 into the intravesicular space 
(Long et al., 2010). The uptake into proteoliposomes is presumably due to the CusA active 
transport activity.  
In addition to the above experiment, we investigated the methionine residues that were 
shown to be important for copper and silver tolerances with the above transport assay.  We 
expressed, purified and reconstituted the CusA mutants, M573I, M623I and M672I, into 
liposomes encapsulated with the same fluorescence indicator.  As expected, these mutant 
transporters do not take up Ag
+
 from the extravesicular medium of the proteoliposomes (Long et 
al., 2010). It is clear that even single point mutations M573I, M623I or M672I abolish the 
process of metal transport across the membrane.  Thus, it is expected that this three-methionine 
site is requisite for both metal binding and export.   
We then purified the mutants, M391I, M486I and M755I, and reconstituted them into 
liposomes.  In these three cases, the fluorescence signals did not attenuate as indicated by the 
stopped-flow assay (Long et al., 2010). When compared with the result from the wild-type CusA, 
this suggests that the M391I, M486I and M755I mutant transporters are unable to actively 
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transport Ag
+
 across the membrane.  Our collective experiments provide direct compelling 
evidence that CusA is capable of taking up Ag
+
 from the cytoplasm. 
The crystal structure of CusA suggests that the charged residues D405, E939 and K984 in 
the transmembrane domain may be important for proton translocation.  When reconstituted into 
liposomes, mutant transporters (D405A, E939A and K984A) do not take up Ag
+
 into the 
intravesicular space (Long et al., 2010)
,
 thus confirming the importance of D405, E939 and K984 
for the function of the pump. 
Dynamics Simulation 
It is likely that CusA operates through an alternating-access mechanism (Murakami et al., 
2006; Seeger et al., 2006; Sennhauser et al., 2007). The dynamics simulation of the trimeric 
CusA pump using elastic network model
 
(Atilgan et al., 2001) was then performed.  The 
calculation indeed suggests that CusA functions through three coupled motions in which the 
periplasmic cleft formed by sub-domains PC1 and PC2 alternately open and close (Long et al., 
2010).
 
The CusBA Adaptor-Transporter Efflux Complex 
Co-crystal structure of the CusBA adaptor-transporter complex 
The co-crystal structure of CusBA was determined to a resolution of 2.90 Å, with the 
final structure includes 93% of the total amino acids (pdb code:3NE5) (Su et al., 2011).  The 
structure suggests that each protomer of CusA specifically interacts with two elongated 
molecules of CusB (molecules 1 and 2) at the upper half portion of the periplasmic domain 
(Figure 6A).  The two CusB adaptors are tilted at an angle of ~50
o
 with respect to the membrane 
surface, and establish a close fit with the transporter at the concave surface formed by Domains 1 
and 2 of the adaptor.  It is found that molecule 1 of CusB contacts mainly the upper regions of 
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PN2 and PC1, and the DN sub-domain of CusA.  Molecule 2 of CusB, however, predominantly 
bridges to the upper regions of PC1 and PC2, and also the sub-domain DC of the pump.  These 
two adaptor molecules are also seen to specifically contact one another, primarily through 
Domains 1, 2 and 3 of these two elongated molecules.  The trimeric CusA pump therefore 
directly contacts six CusB adaptor molecules, which form a channel at the top of the CusA trimer 
(Figure 6B). 
The overall conformation of the CusA protomer in the complex resembles the apo-CusA 
structure (Long et al., 2010).  Superimposition of these two structures
 
results in an RMSD of 
only 1.0 Å for 1,019 C atoms.  For the CusB protomers, two distinct conformations of this 
adaptor are captured in the complex.  When we superimpose these two elongated protein 
structures high RMSD of 7.5 Å is observed for the 321 C atoms, suggesting that the 
conformations of these two protomers are quite different.  Interestingly, a comparison of these 
two molecules with the two previously determined structures of CusB (Su et al., 2009) indicates 
that the four molecules display four distinct conformations, presumably representing different 
transient states of this membrane fusion protein.  This observation is consistent with the previous 
finding that these membrane fusion proteins are highly flexible (Mikolosko et al., 2006; 
Symmons et al., 2009; Su et al., 2009), with the ability to change their conformations upon 
ligand binding (Bagai et al., 2007; De Angelis et al., 2010).  Indeed, it has been demonstrated 
that binding of metal ions trigger significant conformational changes in the CusB (Bagai et al., 
2007) and ZneB (De Angelis et al., 2010) adaptor proteins. 
Previously, it was found that the N and C-terminal ends (residue 29-88 and 386-407) of 
the CusB adaptor are intrinsically disordered and cannot be identified in the electron density 
maps of the CusB crystals (Su et al., 2009).  Here, the co-crystal structure suggests that this 
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region forms several short -helices.  In molecule 1 of CusB, residues 392-399 at the C-terminal 
end form a short -helix.  However, residues 79-95 of the N-terminus feature a long random coil 
and these amino acids are located immediately outside the cleft formed between sub-domains 
PC1 and PC2 of the CusA pump.  For molecule 2 of CusB, the N-terminal residues 79-85 and 
86-92 participate to form a random coil and a short -helix, respectively.  However, the C-
terminal residues 382-392 and 394-400 appear to create two short -helices.  Like molecule 1 of 
CusB, the N-terminus of molecule 2 of CusB is near the periplasmic cleft of the pump (Figure 6).   
It has been proposed that the N-terminal residues M49, M64 and M66 of CusB form a 
three-methionine metal-binding site (Bagai et al., 2007).  Although these three methionine 
residues cannot be identified in the electron density maps of our co-crystal, the co-crystal 
structure does show that the N-terminal tails of both molecule 1 and 2 of the CusB adaptors are 
located outside the cleft formed between PC1 and PC2 of the CusA pump.  On the basis of this 
structure, it is possible that CusB might help to transfer the metal ions via the N-terminal three-
methionine binding site into the periplasmic cleft of CusA. 
CusA and CusB interactions 
Intriguingly, molecule 1 of CusB interacts predominantly with CusA through charge-
charge interactions.  Residues K95, D386, E388 and R397 of this CusB molecule form four salt 
bridges with D155, R771, R777 and E584 of CusA, respectively (Figure 7A).  In addition, T89, 
the backbone oxygen of N91, and R292 of molecule 1 of CusB form hydrogen bonds with K594, 
R147, and the backbone oxygen of Q198 of CusA to secure the interaction (Su et al., 2011).  
However, the interaction between molecule 2 of CusB and CusA appears to be governed 
principally by charge-dipole and dipole-dipole interactions.  Specifically, Q108, S109, S253 and 
N312 of CusB (molecule 2) form hydrogen bonds with Q785, Q194, D800 and Q198 of CusA, 
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respectively (Figure 7B).  The backbone oxygens of L92 and T335 of this CusB molecule also 
contribute two additional hydrogen bonds with the side chains of K591 and T808 of the CusA 
pump to anchor the proteins (Su et al., 2011). 
CusB and CusB interactions 
For CusB-CusB interactions, it appears that molecule 1 of CusB makes a close contact 
with molecule 2 of CusB.  Domains 1-3 of these two molecules are involved in the binding 
(Figure 8A).  Residues E118, Y119, R186, E252 and R292 of molecule 1 of CusB participate to 
form hydrogen bonds with residues T139, D142, T206, N312 and N113 of molecule 2 of CusB, 
respectively (Su et al., 2011). Further, molecule 1 of CusB also contributes to contact molecule 6 
of CusB, which is anchored to the next subunit of CusA (Figure 8B).  The majority of the 
interactions come from Domains 2 and 3 of these two molecules.  Particularly, residues N113, 
N228, and N312 of molecule 1 of CusB pair up with R292, the backbone oxygen of A126, and 
E252 of molecule 6 of CusB to form three hydrogen bonds.  In addition, D142 of molecule 1 of 
CusB participates to form two hydrogen bonds with Y119 and R297 of molecule 6 of CusB to 
secure the binding (Su et al., 2011). 
The hexameric CusB channel 
The co-crystal structure suggests that CusB forms a hexamer above the trimeric CusA 
pump (Figure 9).  This hexameric arrangement allows the membrane fusion proteins to create a 
funnel-like structure with the central channel formed along the crystallographic threefold 
symmetry axis.  Six of these CusB protomers utilize a side-by-side fashion to pack against one 
another to form this funnel.  In view of the structure, it appears that Domain 1 and the lower half 
of Domain 2 of CusB primarily create a cap-like structure whereas the upper half of Domain 2, 
Domain 3 and Domain 4 of the adaptor contribute to the central channel of the funnel (Figure 
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9A).  The inner surface of the cap fits closely with the outer surface of the upper portion of the 
periplasmic domain of the CusA trimer.  The channel formed above the cap of the adaptor is ~62 
Å long with an average internal diameter of ~37 Å.  Thus, the interior of the channel gives rise to 
a large elongated cavity with a volume of ~65,000 Å
3
.  The lower half of the channel is primarily 
created by -barrels whereas the upper half is an all -helical tunnel.  Presumably, this channel is 
filled with solvent molecules.  The diameter of the channel is gradually constricted and then 
dilated as it approaches the outer membrane.  Thus, the -helices of Domain 4 create an inverted 
conical structure.  The narrowest section of the central channel is located at residue D232, which 
is close to the hinge region between Domains 3 and 4 of the membrane fusion protein (Figure 
9B).  The widest section of the channel appears to form at the top edge with its inner diameter 
approximately equals 56 Å.  The inner surface of the channel is predominantly negatively 
charged, as indicated by the electrostatic surface diagram (Figure 10), which suggests that the 
interior surface of the channel may have the capacity to bind positively charged metal ions. 
The co-crystal structure of CusBA here highlights the structural importance of the 
periplasmic adaptor protein.  Given the fact that six CusB molecules assemble to form a channel 
at the CusA funnel top, this suggests that the adaptor is likely to be involved in the active efflux 
of metal ions.  The hexameric arrangement of these membrane fusion proteins has also been 
observed in the crystal structure of MacA in which six protomers assemble to create a large 
channel (Yum et al., 2009).  Thus, in addition to their role as adaptors to bridge the inner and 
outer membrane efflux components, we can anticipate that these membrane fusion proteins are 
likely to actively participate in extrusion of their substrates. 
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Isothermal titration calorimetry for CusA and CusB binding 
We used isothermal titration calorimetry (ITC) to determine the binding affinity of CusB 
to the CusA pump.  The ITC data indicates an equilibrium dissociation constant of 5.1  0.3 M 
(Su et al., 2011). The titration is characterized by a negative enthalpic contribution (∆H = -22.4  
0.3 kcal/mol), which yields a hyperbolic binding curve.  The entropic contribution (∆S) of this 
binding reaction was found to be -50.9 cal•mol•deg-1.  Interestingly, the molecular ratio for this 
binding reaction based on ITC is one CusA monomer for every two CusB protomers (Su et al., 
2011). This result is indeed confirmed by the crystal structure where each protomer of CusA 
binds two molecules of CusB.  
Recently, artificial peptides called DARPins have been introduced to bind and effectively 
inhibit the AcrB transporter (Sennhauser et al., 2007).  The inhibitor-binding site is found right 
above the cleft formed between PC1 and PC2 of AcrB (Sennhauser et al., 2007).  Interestingly, 
the location of this inhibitor-binding site corresponds to the binding site for molecule 2 of CusB 
in the CusBA complex.  Thus, it is likely that the mechanism of action for these inhibitors may 
be the disruption of the adaptor-transporter interaction by competition.  If this is the case, then a 
proposed AcrB3-AcrA3-TolC3 model (Symmons et al., 2009) containing only one protomer of 
AcrA per AcrB protomer would not be sufficient to form a functional pump.  Indeed, it has been 
recently demonstrated that AcrA and AcrB interact with the stoichiometry of 2:1 adaptor-to-
transporter molar ratio (Tikhonova et al., 2011). 
The CusBA-Cu(I) Complexes 
Crystal structures of the CusBA-Cu(I) complexes 
In the absence of the CusB adaptor, two distinct structures of CusA were obtained by X-
ray crystallography (Long et al., 2010). These structures most likely capture two different 
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conformational states of the pump in the transport cycle.  The apo-CusA conformation should 
represent the “resting” state where the external periplasmic cleft is closed.  However, the Cu(I) 
and Ag(I)-bound CusA structures should correspond to the “binding” state where the periplasmic 
cleft is open.  Upon metal ion transport, the pump goes through other transient states to actively 
remove the metal ions.  Recently, the co-crystal structures of the CusBA-Cu(I) complexes have 
been determined.  These structures should represent different intermediates transitioning between 
the “binding” and “resting” states in the transport cycle. 
There are three distinct conformations of CusBA-Cu(I) based on the crystal structures 
(pdb codes: 3T56, 3T51 and 3T53) (Su et al., 2012).  These conformations were designated as 
“pre-extrusion 1”, “pre-extrusion 2” and “extrusion” states (Figure 11).  The conformation of the 
“pre-extrusion 1” state appears to be similar to but is also different from the “binding” structure, 
where the periplasmic cleft is open.  However, the conformation of the “pre-extrusion 2” state 
seems to be closer to but is distinct from the “resting” structure of the pump.  In this 
conformation, the periplasmic cleft is closed.  In the “pre-extrusion 1” state, a single bound Cu(I) 
is found to coordinate residues M573, M623 and M672, which forms the distinct three-
methionine ion binding site inside the cleft of the periplasmic domain of CusA.  Surprisingly, the 
nearby conserved charged residue E625 seems to be involved in the binding (Figure 12).  In 
comparison with the structure of the “binding” state, the horizontal helix, formed by residues 
665-675, inside the cleft of the structure of “pre-extrusion 1” state is lower in position (Figure 
13).  The change can be interpreted as a 3
o
 downward tilting motion of the C-terminal end of the 
horizontal helix in this structure when compared with the CusA-Cu(I) form.  This motion also 
shifts M672 away from M573 and M623, seemingly to disassemble the three-sulfur coordination 
site and to release the bound Cu(I) ion from this site.  In contrast to the “binding” and “resting” 
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structures, no continuous channel is found in each CusA protomer of “pre-extrusion 1” state as 
indicated by the program CAVER (Figure 12A).  
In the “pre-extrusion 2” state, the channel formed by the methionine relay network of 
each protomer of CusA has been closed up (Su et al., 2012).  The only cavity that can be 
identified is the space nearby the copper signal (Figure 12B and C).  This copper signal is found 
in the familiar three-methionine binding site formed by M573, M623 and M672.  However, its 
binding mode is quite distinct from that found in the “binding” state.  First, the C-terminal end of 
the horizontal helix (residues 665-675) significantly tilts downward by ~10
o
 in this “pre-
extrusion 2” state in comparison with the “binding” form.  This motion shifts the position of 
M672 away from M573 and M623, probably weakening the binding for Cu(I) within the 
methionine triad.  Secondly, coupled with this movement, the side chain of a conserved anionic 
charged residue E625, located deep inside the periplasmic cleft, is found to flip towards the 
bound Cu(I) and interact with this ion by electrostatic interaction.  In addition, a cluster of 
conserved charged residues, including R83, E567, D617, E625, R669 and K678, is found nearby 
this copper signal.  Interestingly, these conserved charged residues line along the metal-ion 
transport channel formed by the methionine relay network (Figure 14), suggesting that these 
charged residues may be important for the transporter’s functioning. 
In addition to the above movements, the transmembrane helices 5 and 6 (residues 447-
495) are found to shift downward by 5 Å with respect to the membrane plane in both “pre-
extrusion 1” and “pre-extrusion 2” states, mimicking the change in position of the horizontal 
helix, when compared with the conformation of the “binding” state (Figure 13).  
The conformation of the “extrusion” state is nearly identical to that of apo-CusBA, and 
one bound Cu(I) is found to coordinate M573, M623, M672 and E625 (Figure 12D).  The 
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conformation of CusA in this complex structure is also very similar to that of apo-CusA at the 
“resting” state.  However, a closer inspection of these structures suggests that the CusA 
protomers in the two CusBA complexes are in a different conformational state when compared 
with the apo-CusA form.  Binding of the CusB adaptor triggers a subtler but significant 
conformational change at the upper portion of subdomain PC1 of the CusA transporter.  It is 
observed that a short C-terminal helix (residues 391-400) of molecule 1 of CusB directly 
interacts with and pushes a helix (residues 582-589) located at the upper half of PC1 of CusA 
(Figure 13).  The consequence is that the N-terminal end of this PC1 helix is found to tilt 
downwards by 8
o
 in the CusBA form in comparison with the apo-CusA structure.  This tilting 
motion in turn further pushes a loop (residues 609-626) located right below the PC1 helix 
downward.  On the basis of these structures, CusB may be involved in tuning the width of the 
channel formed by the methionine metal-ion relay network to its optimal level through the above 
mechanism. 
In the “pre-extrusion 2” structures, the channel formed by the methionine metal-ion relay 
network is occluded (Figure 12B and C).  It is observed that the region nearby E622 and M812 
form the narrowest region immediately after the three-methionine binding site. Interestingly, 
M812 was found to be significant in relieving copper sensitivity of E. coli
 
(Franke et al., 2003).  
Thus, an empirical measurement defined as the C-C distance between E622 and M812 was 
used to identify the degree of opening of the channel.  These distances are 13 Å, 12 Å, 10 Å, 10 
Å and 11 Å for the “resting”, “binding”, “pre-extrusion 1”, “pre-extrusion 2” and “extrusion” 
states, respectively.  In the “resting” state, the channel is fully open.  This channel is also open 
and is believed to be at its optimal degree of opening in the “extrusion” form (Su et al., 2012). 
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Functional studies of the conserved charged residues 
The structures of CusBA-Cu(I) highlight the importance of charged residues for the 
transporter’s functioning.  These conserved charged residues (R83, E567, D617, E625, R669 and 
K678) seem to form a network and line along the wall of the methionine relay tunnel in the 
periplasmic domain of CusA.  These residues were mutated into alanines (R83A, E567A, 
D617A, E625A, R669A, K678A) or aspartate (E625D), and the corresponding mutant 
transporters were expressed in BL21(DE3)∆cueO∆cusA which lacks both the cueO and cusA 
genes.  The ability of these mutant transporters to confer copper resistance was then tested in 
vivo using susceptibility assay.  Similar to the methionine mutations mentioned earlier, the 
results indicate that all these CusA mutants are unable to relieve the copper sensitivity of strain 
BL21(DE3)∆cueO∆cusA, suggesting that these residues are critical for the function of the pump 
(Su et al., 2012).    
The purified R83A, E567A, D617A, E625A, R669A and K678A mutant proteins, which 
are shown to abolish the function of the pump, were then reconstituted into liposomes containing 
the fluorescent indicator PGSK in the intravesicular space, respectively.  A stopped-flow 
transport assay was used to determine whether these proteoliposomes can capture metal ions 
from the extravesicular medium.  Unlike the wild-type CusA pump, the results suggest that these 
mutant transporters are incapable of taking up Ag
+
 from the extravesicular medium into the 
intravesicular space of the proteoliposomes (Su et al., 2012).  These collective experiments 
provide compelling evidence that these conserved charged residues are critical for the 
transporter’s functioning. 
The stopped-flow assay was further used to study the transport activity of the 
reconstituted CusBA proteoliposomes.  The results suggest that the CusBA proteoliposomes are 
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more active than those liposomes containing CusA only for metal transport as indicated by the 
position of the 50% attenuation of the fluorescent signal (Su et al., 2012).  No transport activity 
has been observed in liposomes containing CusB only, indicating that these CusB 
protoliposomes cannot uptake silver ions (Su et al., 2012). 
Sequential transitions of the CusA efflux pump 
Four lines of evidence suggest that the structures identified can be understood in terms of 
sequential transition of conformations leading to the extrusion of metal ions from the CusA 
pump (Figure 15).  First is the sequential decrease in distance between subdomains PC1 and PC2 
from the “binding” to “resting” states.  This change highlights the sequential movements of 
CusA upon transiting from one state to the other.  Second is the subtler shift in position of the 
horizontal helix leading to the departure of M672 from the methionine triad and a release of the 
bound Cu(I) from these methionines.  In addition, transmembrane helices 5 and 6 are found to 
shift in position at different conformational states (Figure 15), mimicking the change of the 
horizontal helix.  Last is a smaller change in conformation of subdomain PC1 of CusA upon 
CusB binding, which in turn controls the degree of opening of the channel formed by the 
methionine relay network.  These structures also suggest that the CusB adaptor may play an 
essential role in tuning the extent of channel opening upon conformational transition through 
different states. 
The co-crystal structures of CusBA-Cu(I) extend our knowledge on how successive 
motions in the CusBA efflux pump are coordinated and how CusBA extrudes the bound metal 
ions.  This protein complex undergoes cycles of conformational changes that drive the passage of 
the metal ions.  In the absence of both CusB and Cu(I) or Ag(I), the CusA pump prefers the 
“resting” conformation where the periplasmic cleft between subdomains PC1 and PC2 are 
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closed.  Cu(I) or Ag(I) binding triggers a large conformational change where subdomain PC2 
performs a 30
o
 swing to open this cleft.  In the presence of CusB, the subsequent steps may be a 
transitions to the “pre-extrusion 1” and then “pre-extrusion 2” states in which PC2 is found to 
swing back to close the cleft (Figure 16).  The majority of the channel formed by the methionine 
relay network becomes occluded at the “pre-extrusion 2” state.  Subsequently, the last step is a 
transition to the “extrusion” form where CusB is responsible for stabilizing the conformation of 
this state, and for tuning the channel at the optimal degree of opening to conduct metal ion 
export.  As mentioned earlier, it is very likely that the CusCBA pump operates through an 
alternating-access mechanism (Murakami et al., 2006; Seeger et al., 2006; Sennhauser et al., 
2007). Indeed, functional dynamics simulation has already suggested that the periplasmic cleft of 
CusA may alternately open and close upon metal transport (Long et al., 2010). As the crystal 
structures of the CusBA adaptor-transporter complex depict that there are several intermediates 
participating in the transport cycle, it is difficult to correlate all these conformational states to 
those of AcrB.  Nonetheless, the “binding” state of the CusBA system should correspond to the 
“T” state of the AcrB pump (Murakami et al., 2006; Seeger et al., 2006; Sennhauser et al., 2007). 
Unresolved Problem 
Clearly, the CusA, CusB and CusC proteins need to assemble in order to form the 
tripartite CusCBA complex to export metal ions.  Although the co-crystal structure of the CusBA 
adaptor-transporter complex has been determined, it is unclear how CusC interacts with CusBA 
to function.  The crystal structure of CusC (Kulathila et al., 2011) suggests that this channel 
protein resembles the architectures of E. coli TolC (Koronakis et al., 2000) and P. aeruginosa 
OprM (Akama et al., 2004).  To understand how the CusBA complex interacts with CusC, 
molecular dynamics simulation was used to rigidly dock the trimeric CusC channel to the crystal 
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form of the hexameric CusB channel bound to the trimeric CusA pump.  The final fitting 
CusCBA model, which is in the form of CusC3-CusB6-CusA3, was then constructed.  This model 
represents a 750 kDa tripartite efflux complex spanning both the inner and outer membranes of 
E. coli to extrude Cu(I)/Ag(I) (Figure 17).  Nonetheless, it is necessary to obtain the co-crystal 
structure of the entire CusCBA tripartite efflux complex to understand how these three efflux 
proteins assemble as a functional unit.  
Proposed Mechanism For Metal-Ion Export 
The metal ions can enter the CusA pump via the periplasmic cleft as well as the 
cytoplasm (Figure 14).  Presumably, the methionine pairs/clusters are responsible for metal ion 
transport.  In the transmembrane regions, these methionine pairs are ~15 Å apart.  Thus, it is 
possible that a direct transfer of metal ions from one methionine pairs to the other contributes to 
deliver the ions through the inner membrane. (Figure 18).  It is believed that CusA 
predominately carries out metal ion efflux through the periplasm (Kim et al., 2011). Thus, the 
major path for taking up metals should be across the cleft in the periplasmic space.  We propose 
that the CusA transporter utilizes methionine pairs/clusters to export Cu(I) and Ag(I).  The 
periplasmic cleft of CusA presumably remains closed when there is no Cu(I)/Ag(I).  In the 
presence of Cu(I) or Ag(I) ions, the periplasmic cleft opens.  Metal ions could enter the three-
methionine binding-site, formed by M573, M623 and M672, inside the cleft between sub-
domains PN2 and PC1 on the periplasmic portion of CusA or via the methionine pairs within the 
transmembrane domain of the pump.  It has been demonstrated that the chaperone protein CusF 
can directly transfer its bound Cu(I) to the CusB membrane fusion protein (Bagai et al., 2008).  
Thus, it is likely that CusF is responsible for delivering metal ions to the CusCBA tripartite 
efflux system within the periplasm.  There is a chance that the initial step of metal transport 
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through the periplasmic cleft of the CusA pump may involve a direct transfer from CusF to the 
previously proposed three-methionine metal binding site (Bagai et al., 2007) at the long N-
terminal tail of CusB.  Based on the co-crystal structure of CusBA, each flexible tail of CusB is 
located near the PN2/PC1 cleft of the CusA pump.  Thus, the second step could well be a 
deliverance of the bound metal ion from CusB to the three-methionine cluster (M573, M623 and 
M672) inside the periplasmic cleft of CusA (Long et al., 2010).  The bound metal ion could then 
be released to the nearest methionine pair (M271-M755) located directly above the three-
methionine metal binding site (Figure 5), from which the ion could be released into the central 
funnel of CusA and eventually to the CusC channel for final extrusion.  Genetic data and 
transport assay have shown that the conserved charged residues lining the methionine relay 
channel are essential for the transporter’s functioning (Figure 14).  Therefore, it is possible that 
these conserved charged amino acids are responsible for passing the transported metal ion along 
from one residue to another in the methionine relay channel.  
During the transport cycle, the CusBA efflux complex must go through different transient 
states, including the “resting”, “binding”, “pre-extrusion 1”, “pre-extrusion 2” and “extrusion” 
conformations, to complete the transport cycle (Figures 15 and 16).  Thus, in coordination with 
the motion of the periplasmic cleft, the transmembrane portion of the methionine relay channel 
should also be synchronized to open and close to accommodate for the export of metal ions. 
It is not yet known whether the interior of the hexameric CusB channel forms part of the 
extrusion pathway for Cu(I) and Ag(I).  Based on the crystal structures of CusBA (Su et al., 
2011) and CusC (Kulathila et al., 2011), the interior surface of both the hexameric CusB and 
trimeric CusC channels are predominantly negatively charged and that the interior surface of 
CusC is more electronegative.  Thus, it is likely that the last step of transport of cationic Cu(I) 
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and Ag(I) is facilitated by the negative potential gradient created by the CusB and CusC 
channels.  During metal-ion extrusion, a large conformational change of CusC may occur to open 
this outer membrane channel, similar to the cases of TolC (Vaccaro et al., 2008) and OprM 
(Phan et al., 2010).  Exactly what this tripartite efflux system’s mechanism is must await 
confirmation by elucidation of additional crystal structures of the CusCBA tripartite complex.  
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Figures and tables 
 
 
 
 
 
Fig 1.  Model of the CusCBA tripartite efflux pump.  The three components of this HME-RND 
system form a CusCBA efflux complex, which spans both the inner and outer membranes of E. 
coli to export Cu
+
 and Ag
+
 directly out of the cell.  The periplasmic chaperone CusF is involved 
in delivering the metal ions to the CusCBA complex.  Heavy-metal efflux is driven by the 
proton-motive force.  
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Fig. 2.  Crystal structure of the CusB membrane fusion protein.  (A) Ribbon diagram of the two 
protomers in the asymmetric unit of the crystal.  (B) The four domains of each protomer in 
ribbon diagram. Domain 1 is formed by the N and C-terminal ends of the polypeptide (residues 
89-102 and 324-385) and interacts with the periplasmic domain of the CusA efflux pump. 
Domain 2 is formed by residues 105-115 and 243-320 and comprises six -strands and one short 
-helix.  Domain 3 consists of residues 121-154 and 207-239, with a majority of these residues 
folding into eight -strands. Domain 4 is comprised of residues 156-205, forming an all-helical 
domain.  It is folded into an anti-parallel, three-helix bundle that is not found in other known 
protein structures in the MFP family. 
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Fig. 3. Crystal structures of the CusA efflux pump. (A) Ribbon diagram of the CusA homotrimer 
viewed in the membrane plane. Each molecule is labeled with a different color:  molecule 1 is 
purple, molecule 2 is orange, and molecule 3 is green. Each subunit of CusA consists of 12 
transmembrane helices (TM1-TM12) and a large periplasmic domain formed by two periplasmic 
loops between TM1 and TM2, and TM7 and TM8, respectively. (B) Ribbon diagram of the 
CusA homotrimer subdomains as viewed from the top. The six subdomains are PN1 (red), PN2 
(blue), PC1 (yellow), PC2 (teal), DN (green) and DC (pink). 
 
  
93 
 
 
 
Fig. 4A 
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Fig 4.  Comparison of the apo and metal bound structures of CusA.  (A) Superposition of a 
monomer of apo-CusA onto a monomer of Cu(I) bound-CusA.  The bound Cu(I) is in sphere.  
The arrow represents a major swing of the PC2 sub-domain initiated by Cu(I) binding.  (B) 
Conformational changes of the periplasmic domain of CusA.  The conformation of each sub-
domain of CusA before (left) and after (right) Cu(I) binding.  The periplasmic cleft formed 
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between PC1 and PC2 is opened after Cu(I) binding.  The bound coppers in the CusA-Cu(I) 
structure are blue.  M573, M623 and M672 forming a metal binding site at the periplasmic cleft 
are shown in stick form.  (C) The changes in conformation of the horizontal helix and TM8, are 
shown in a superimposition of the structures of apo and Cu(I)-bound CusA.  The bound Cu(I) is 
shown as a sphere.  Anomalous map of the bound Cu(I) is contoured at 8.  M573, M623 and 
M672 are shown as sticks.  (D) The Ag(I) binding site.  The bound Ag(I) is shown as a sphere.  
Anomalous map of the bound Ag(I) is contoured at 10. 
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Fig. 5.  Channel in the CusA pump.  The channel formed by the front protomer of apo-CusA 
leading through the transmembrane and periplasmic domains is shown.  This channel was 
calculated using the position of the sulfur atom of residue M672 as a starting point.  The 11 
methionines forming the relay network are in spheres.  Two other CusA protomers behind the 
front protomer are also shown as wires. 
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Fig. 6. Crystal structures of the CusBA adaptor-transporter efflux complex.  (A) The asymmetric 
unit shows two CusB molecules (colors green and red) interacting with one CusA molecule (light 
orange).  Domains 1-4 of CusB are labeled.  (B) The full structure showing the hexameric CusB 
adaptor structure interacting with the trimeric CusA pump. Each CusB molecule is indicated in a 
different color: green, red, light blue, yellow, purple, and orange. Each CusA molecule is 
indicated in different, lighter colors: light orange, light red, and light green.  
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Fig.7.  Interactions between CusA and CusB in ribbon format. Important residues involved in 
interactions between the molecules are shown as sticks. (A) Interaction between molecule 1 of 
CusB and CusA, with each molecule. Residues K95, D386, E388 and R397 of CusB form four 
salt bridges with D155, R771, R777 and E584 of CusA, respectively. In addition, T89, the 
backbone oxygen of N91, and R292 of molecule 1 of CusB form hydrogen bonds with K594, 
R147, and the backbone oxygen of Q198 of CusA. (B) Interaction between molecule 2 of CusB 
and CusA.  Residues Q108, S109, S253 and N312 of CusB form hydrogen bonds with Q785, 
Q194, D800 and Q198 of CusA, respectively. The backbone oxygens of L92 and T335 of this 
CusB molecule also contribute two additional hydrogen bonds, with the side chains of K591 and 
T808 of CusA, anchoring the proteins. 
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Fig. 8.  Interactions between the CusB molecules in forming the hexameric structure in ribbon 
format. Important residues involved in interactions between the molecules are shown as sticks. 
(A) Interactions between molecule 1 and molecule 2 of CusB. Residues E118, Y119, R186, E252 
and R292 of molecule 1 of CusB participate to form hydrogen bonds with residues T139, D142, 
T206, N312 and N113 of molecule 2 of CusB, respectively. (B) Interactions between molecule 1 
and molecule 6 of CusB. Residues N113, N228 and N312 of molecule 1 of CusB pair with R292, 
the backbone oxygen of A126, and E252 of molecule 6 of CusB, respectively, to form three 
hydrogen bonds. D142 of molecule 1 of CusB also participates to form two hydrogen bonds, 
with Y119 and R297 of molecule 6 of CusB.  
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Fig. 9.  Structure of the hexameric CusB channel.  (A) Side view of the CusB channel. The six 
molecules forming the hexameric channel are labeled. Domain 1 and the lower half of domain 2 
of the molecules of the CusB hexamer form a cap, whereas the upper half of domain 2, together 
with domains 3 and 4, of these molecules creates a channel. (B) Top view of the CusB channel 
with the narrowest point (D232) shown as a stick. The six molecules are the same as depicted in 
(A). The internal diameter in the narrowest region is ~18 Å. 
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Fig. 10.  Electrostatic surface potential of the hexameric CusB channel.  (A) Side view of the 
electrostatic surface potential of the hexameric CusB channel.  This view shows the cap and 
channel regions formed by the CusB hexamer.  (B) Top view of the electrostatic surface potential 
of the hexameric CusB channel.  The widest section of the hexameric channel appears to form at 
the top edge with its internal diameter of ~56 Å. 
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Fig. 11.  Structures of the CusBA-Cu(I) efflux complexes.  (A) Ribbon diagram of the structure 
of form Ia viewed in the membrane plane.  The bound copper is shown as a sphere.  This 
structure represents the “pre-extrusion 1” state of the pump.  (B) Ribbon diagram of the structure 
of form Ib viewed in the membrane plane.  The bound copper is shown as a sphere.  This 
structure represents the “pre-extrusion 2” state of the pump.  (C) Ribbon diagram of the structure 
of form II viewed in the membrane plane.  The bound copper is shown as a sphere.  This 
structure represents the “pre-extrusion 2” state of the pump.  (D) Ribbon diagram of the structure 
of form III viewed in the membrane plane.  The bound copper is shown as a sphere.  This 
structure represents the “extrusion” state of the pump.  For clarity, only the periplasmic domain 
(subdomains PN2, PC1 and PC2) and part of the transmembrane region of CusA are shown in 
(A)-(D).  The molecules of CusB in each complex are not included.     
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Fig. 12.  Formation of channels at different conformational states.  (A) The channel formed by a 
protomer of the form Ia structure of CusBA at the periplasmic domain is shown.  The bound 
Cu(I) is shown as a sphere.  M573, M623, M672 and E625, which form a Cu(I) binding site, are 
shown as sticks.  The CusA and two CusB protomers are ribbons.  (B) The channel formed by a 
protomer of the form Ib structure of CusBA at the periplasmic domain is shown.  The bound 
Cu(I) is shown as a sphere.  Anomalous map of the bound Cu(I) is contoured at 3.  M573, 
M623, M672 and E625, which form a Cu(I) binding site of the form Ib conformation, are shown 
as sticks.  The CusA and two CusB protomers are in ribbons.  (C) The channel formed by a 
protomer of the form II structure of CusBA at the periplasmic domain is shown.  The bound 
Cu(I) ion is shown as a sphere.  Anomalous map of bound Cu(I) ion is contoured at 3.  
Residues forming the Cu(I) binding sites M573, M623, E625 and M672 are shown as sticks.  
The CusA and two CusB protomers are in ribbons.  (D) The channel formed by a protomer of the 
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form III structure of CusBA at the periplasmic domain is shown.  The bound Cu(I) is shown as a 
sphere.  Anomalous map of the bound Cu(I) is contoured at 3.  M573, M623, E625 and M672, 
which form the Cu(I) binding site, are shown as sticks.  The CusA and two CusB protomers are 
in ribbons. 
 
 
 
 
Fig. 13.  Different conformational states of CusBA-Cu(I).  (A) Superimposition of subdomain 
PC2 and TM8 of each state of the pump.  The arrow indicates a 30
o
 swing of PC2 upon 
conformational transition from the “pre-extrusion 1” to “pre-extrusion 2” and “extrusion” states.  
The structures of forms Ia, II and III are used to represent the “pre-extrusion 1”, “pre-extrusion 
2” and “extrusion” states, respectively.  (B) Superimposition of subdomain PC1 and the 
horizontal helix of each state of the pump.  The figure illustrates the change in conformations of 
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the PC1 helix (residues 582-589) and the flexible loop (residues 609-626) upon CusB binding.  
For clarity, only the short C-terminal helix (residues 391-400) of molecule 1 of CusB is included.  
The change in conformation of the horizontal helix at different states of the pump is also shown 
in this superimposition. (C) Superimposition of the transmembrane helices 5 (TM5) and 6 (TM6) 
of each state of the pump.  The figure illustrates the change in positions of TM5 and TM6 
(residues 447-495) within the transport cycle.  As both forms Ib and II are in the same state, the 
conformation of form Ib is not included in (A)-(C) for clarity. 
 
 
 
 
Fig. 14.  Cu(I) binding site and conserved charged residues.  This is a schematic representation 
of the CusA channel.  The conserved residues R83, E567, D617, E625, R669 and K678, lining 
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the channel at the periplasmic domain are indicated.  The dotted circle marks the location of the 
Cu(I) binding site formed by the methionine triad M573, M623 and M672.  The paths for metal 
transport through the periplasmic cleft and transmembrane region are illustrated with black 
curves. 
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Fig. 15.  Sequential conformational transition of the CusBA pump.  This figure depicts stepwise 
motions of CusA in the adaptor-transporter complex transitioning between the “resting” and 
“extrusion” states (A, “resting” state; B, “binding” state; C, “pre-extrusion 1” state; D, “pre-
extrusion 2” state; E, “extrusion” state).  For clarity, only subdomains PC1 and PC2 in the 
periplasmic domain and transmembrane helices 5, 6 and 8 in the transmembrane region of CusA 
are shown.  The bound copper is in sphere.  The arrows indicate the change in conformation of 
the protein within the transport cycle. 
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Fig. 16.  Proposed model of metal ion export within the transport cycle.  The model is based on 
different structures obtained by X-ray crystallography.  The angle of inclination of the horizontal 
helix at each state is shown in the figure.  For clarity, the front protomers (one CusA and two 
CusB molecules) are not included. 
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Fig. 17.  Docking of CusC to CusBA.  (A) The -helical end of CusC interacts with the -
helices (Domain 4) of CusB in the CusBA complex.  (B) The funnel top of CusA, -helical end 
of CusC and Domain 2 of CusB contact one another when the CusC channel slides further down 
the hexameric CusB channel.  
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Fig. 18.  Schematic diagram of the methionine pairs in the transmembrane regions of CusA in 
transport of a Cu(I) ion.  After interacting with the ion (A), one of the methionines in the pair 
moves the ion towards an outreached neighboring methionine on the next level (B, D). The ion 
then interacts with the second methionine of the new pair (C, E) before being handed off to a 
neighboring methionine on the next level. 
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Table 1.  The RND efflux pumps of Escherichia coli. 
 
RND 
protein 
Subfamily Function MFP OMC References 
AcrB HAE Multi-drug efflux pump (conferring resistance 
to chloramphenicol, tetracycline, minocycline, 
erythromycin, nalidixic acid, norfloxacin, 
enoxacin, doxorubicin, novobiocin, rifampin, 
trimethoprim, acriflavine, crystal violet, 
ethidium bromide, rhodamine 6G, 
tetraphenylphosphonium bromide, 
benzalkonium, Triton X-100, sodium dodecyl 
sulfate, deoxycholate, taurocholate, etc.) 
AcrA TolC Zgurskaya and 
Nikaido, 1999; 
Nishino and 
Yamaguchi, 2001 
AcrD HAE Multi-drug efflux pump (conferring resistance 
to aminoglycosides, novobiocin, sodium 
dodecyl sulfate, and deoxycholate) 
AcrA TolC Rosenberg et al., 
2000; Nishino and 
Yamaguchi, 2001; 
Aires and Nikaido, 
2005 
AcrF HAE Multi-drug efflux pump (conferring resistance 
to doxorubicin, acriflavine, ethidium bromide, 
rhodamine 6G, sodium dodecyl sulfate, 
deoxycholate; important in the maintenance of 
cell division) 
AcrE TolC Ma et al., 1993; 
Nishino and 
Yamaguchi, 2001; 
Lau and Zgurskaya, 
2005 
MdtB HAE Multi-drug efflux pump (conferring resistance 
to nalidixic acid, norfloxacin, fosfomycin, 
novobiocin, benzalkonium, sodium dodecyl 
sulfate, and deoxycholate) 
MdtA TolC Nishino and 
Yamaguchi, 2001; 
Baranova and 
Nikaido, 2002; 
Nagakubo et al., 
2002 
MdtC HAE Multi-drug efflux pump (conferring resistance 
to nalidixic acid, norfloxacin, fosfomycin, 
novobiocin, benzalkonium, sodium dodecyl 
sulfate, and deoxycholate) 
MdtA TolC Nishino and 
Yamaguchi, 2001; 
Baranova and 
Nikaido, 2002; 
Nagakubo et al., 
2002 
YhiV HAE Multi-drug efflux pump (conferring resistance 
to erythromycin, doxorubicin, crystal violet, 
ethidium bromide, rhodamine 6G, 
tetraphenylphosphonium bromide, 
benzalkonium, sodium dodecyl sulfate, and 
deoxycholate) 
YhiU TolC Nishino and 
Yamaguchi, 2001; 
Kobayashi, 2001; 
Bohnert et al., 2007 
CusA HME Heavy-metal efflux pump (conferring 
resistance to Cu(I) and Ag(I) ions) 
CusB CusC Nishino and 
Yamaguchi, 2001; 
Franke et al., 2001; 
Franke et al., 2003 
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Abstract 
 The rise of antibiotic-resistant strains of bacteria is a great concern in the modern world. 
The sexually transmitted disease gonorrhea is caused by the bacterium Neisseria gonorrhoeae. 
Due to the overuse of antibiotics, this bacterial infection is making a return, and is harder to treat. 
The bacterium uses various mechanisms to overcome the toxic effects of antibiotics—one of 
which is the efflux pump which prevents antimicrobials from accumulating inside the cell. The 
MtrD and MtrE proteins are two proteins involved in the tripartite efflux pump MtrCDE, which 
confers resistance to many different antimicrobials such as bile salts, fatty acids, and antibiotics. 
Here, we introduce the crystal structures for the MtrD and MtrE proteins. Virtual docking 
suggests that the MtrD pump recognizes and binds to molecule within the periplasmic cleft. 
Further docking studies indicate that the MtrD, MtrE, and predicted MtrC proteins can interact to 
generate an MtrE3-MtrC6-MtrD3 complex model. These findings provide some understanding 
behind the pump’s ability to recognize and efflux multiple types of antimicrobials.  
Introduction 
 Neisseria gonorrhoeae, a Gram-positive bacterium, is the causative agent of the sexually-
transmitted disease gonorrhea and. It is one of the oldest documented diseases plaguing humans, 
and it still remains a significant global problem (1). More than 100 million cases are reported 
annually worldwide, with antibiotic-resistant strains of N. gonorrhoeae on the rise. The 
gonococcus bacterium possesses an intricate mechanism of antigenic variability through 
differential expression of the genome, and it can easily acquire new genetic material such as 
those for antibiotic resistance (1, 2). Gonococci use a number of resistance mechanisms such as 
reduced cell-envelope permeability, target modification, antimicrobial inactivation, and active 
transport of the antimicrobial through the membrane using efflux pumps.  
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 The multidrug efflux pump is considered to be one of the major causes of failures for 
drug-based treatments (3). By simultaneously rendering the bacterium resistant to multiple 
structurally-unrelated compounds, these efflux pumps result in bacterial strains that are resistant 
to most clinically-relevant drugs (3).  
 The best characterized and most clinically-relevant of the multidrug efflux systems in N. 
gonorrhoeae is the MtrCDE tripartite efflux pump (4-7). It is made up of the MtrD inner 
membrane transporter—a member of the HAE-RND protein family (8), the MtrC perplasmic 
protein—a member of the membrane fusion protein family, and the MtrE integral outer 
membrane channel protein. This system provides resistance to antimicrobial agents such as bile 
salts, fatty acids, antibiotics, spermicides, and host-derived cationic antimicrobial peptides (7). 
The efflux pump is capable of enhancing long-term colonization of the mouse vaginal mucosal 
layer; gonococci lacing the MtrCDE system were highly attenuated (9). Thus, the MtrCDE 
system is a prime target for understanding difficult to treat strains of N. gonorrhoeae.  
Overall structures of MtrD and MtrE 
 The crystal structure of MtrD was determined to a 3.53 Å resolution (Table 1), with 97% 
of the amino acids (residues 2-493 and 508-1040) included in the final model (Fig 2a). The 
structure of MtrD is closer to the conformation of the “access” protomer of AcrB. However, the 
superimposition of the two structures resulted in a root mean square deviation of 7.6 Å over 1000 
C-α atoms, suggesting significant differences in the structures (Fig. S1). 
 MtrD is a homotrimer 125 Å long and 95 Å wide (Fig 1b). Each protomer is made up of 
12 transmembrane helices (TM1-TM12). Like other RND transporters, the N-terminal (TM1-
TM6) and C-terminal (TM7-TM12) halves of the MtrD structure are related by a pseudo-twofold 
symmetry. A large periplasmic domain is created by two extensive periplasmic loops connecting 
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TM1 with TM2 and TM7 with TM8, respectively.  As in AcrB (10-18) and MexB (19), this 
periplasmic domain can be divided into six sub-domains: PN1, PN2, PC1, PC2, DN, and DC 
(Figs. 1 and 2).  Sub-domains PN1, PN2, PC1, and PC2 form the pore domain, with PN1 making 
up the central pore and stabilizing the trimeric organization.  Sub-domains DN and DC, however, 
contribute to form the docking domain, presumed to be interacting with the outer membrane 
channel MtrE.  The trimeric MtrD structure suggests that sub-domains PN2, PC1 and PC2 are 
located at the outermost core of the periplasmic domain, facing the periplasm.  Sub-domains PC1 
and PC2 also form an external cleft, and this cleft is open in the MtrD structure (Fig. 1).  Based 
on the co-crystal structure of CusBA (20,21) of the CusCBA tripartite efflux system (22-27), the 
upper regions of PN2, PC1, PC2, and sub-domains DN and DC should directly interact with the 
MtrC membrane fusion protein to form a functional adaptor-transporter complex. 
 The structure of the outer membrane channel protein MtrE was determined to a resolution 
of 3.29 Å (Table 2). The final model consists of 99% the total amino acids (residues 1-445) (Fig 
3a). Superimposition of the MtrE structure with the outermembrane channel protein OprM (PDB 
ID: 1WP1) results in a root mean square deviation of 18.2 Å over 445 C-α stoms, suggesting 
highly significant differences (Fig. S1).  
 Similar to the proteins TolC (28) and OprM (29), MtrE exists as a homotrimer, forming a 
~130 Å long α/β barrel (Fig 3b). Each subunit of the protein contains four β-strands (contributing 
to the 12 stranded outer membrane β-barrel) and eight α-helices 9forming the elongated 
periplasmic α-barrel) (Fig 4). These four -strands (S1, S2, S3 and S4) constitute the -barrel 
domain and are organized in an antiparallel fashion, spanning the outer membrane.  In contrast, 
the elongated periplasmic tunnel of MtrE contains six -helices.  Similar to the structure of 
TolC, two long helices (H3 and H7) are found to extend across the entire length of the 
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periplasmic -helical tunnel.  The -helical tunnel of MtrE also includes two pairs of shorter -
helices, (H2 and H4) and (H6 and H8).  These two pairs of shorter helices stack end-to-end to 
form pseudocontinuous helices, which contribute coiled-coil interactions with the two long 
helices.  The equatorial domain of MtrE is composed of two helices (H1, H5) and the remaining 
elements at this domain are mostly unstructured.  The periplasmic tunnel of MtrE is ~100 Å long 
with an outermost diameter of ~35 Å at the tip of the tunnel.    
The N. gonorrhoeae MtrCDE tripartite efflux system has the advantage that all these 
protein components are encoded by the same operon.  Thus, the interactions between different 
proteins are likely to be specific, facilitating analyses of how different components function 
cooperatively. 
Virtual high throughput screening 
Virtual high throughput ligand screening was then performed to elucidate the nature of 
protein-drug interactions and potential binding sites in the MtrD efflux pump.  AutoDock Vina 
(30) was used to screen small molecules listed in the DrugBank (31) and ZINC (32) libraries.  Of 
the 70,000 screened compounds, it is predicted that the top two antibiotics for MtrD are 
quinupristin and vancomycin (Fig. S2a).  In addition, the best two small chemicals for this pump 
are UCL 1684 and naphthofluorescein (Fig. S2b).  All these substrates are bound deep inside the 
large periplasmic cleft, which form the strongest substrate-binding site of the pump (Fig. 5).  
Specifically, these docked substrates are bound in the same site, which is located behind the 
flexible loop created by residues 608-619 (Fig. 5).  We suspect that this flexible loop may be 
important for drug extrusion.  There is a chance that this loop may swing into the substrate-
binding site during the course of the extrusion process to facilitate drug export.  The binding 
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scores also suggest that the MtrD often used residues D83, S134, R174 and F610 to 
accommodate for the binding of these different ligands. 
Virtual docking of MtrD and MtrE 
It has been reported that the AcrB efflux pump interacts with its corresponding TolC 
channel in the submicromolar range (33).  As we have recently also determined the X-ray 
structure of the MtrE outer membrane channel (34), flexible docking was then carried out to 
investigate the possibility of a direct interaction between the MtrE channel and MtrD efflux 
pump.  A generalized approach to sampling backbone conformations was performed using 
RosettaDock (35), followed by optimizing the side chains and energy minimization.  The 
resulting MtrD-MtrE structure suggests that the -hairpin between H7 and H8 of MtrE contacts 
the -hairpin of subdomain DN of MtrD to form the complex.  Likewise, the -hairpin between 
H3 and H4 of MtrE also directly interacts with the -hairpin of subdomain DC of MtrD, 
stabilizing the complex formation (Fig. 6). 
Predicted structural model of the assembled MtrCDE tripartite efflux complex 
The crystal structure of the periplasmic membrane fusion protein MtrC is not yet 
available.  Among all known structures of membrane fusion proteins in the Protein Data Bank, 
the Pseudomonas aeruginosa MexA channel (36) gives the highest protein sequence identity 
when compared with the amino acids of N. gonorrhoeae MtrC.  Alignment of amino acid 
sequences indicates that these two membrane proteins share 39% identity.  We expect that the 
architecture of MtrC should be highly similar to that of MexA.  We therefore use the crystal 
structure of MexA (pdb code: 2V4D) (36) as a template here to predicted a three-dimensional 
model of MtrC using the program I-TASSER (37). The predicted MtrC structure is indeed 
reminiscent of the MexA adaptor protein, indicating that the MtrC adaptor consists of three -
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strand regions and an -helical domain (Fig. 7). The predicted MtrC protomer model is ~145 Å 
long and ~40 Å wide.    
Predicted structural model of the assembled MtrCDE complex 
Using the crystal structure of the CusBA complex (21) as a template, the predicted MtrC 
structure was docked onto our crystal structure of the MtrD transporter to generate an MtrCD 
complex model.   This predicted MtrCD model resembles the CusBA adaptor-transporter 
complex (21), where six adaptor molecules interact with the trimeric pump to form an MtrC6-
MtrD3 complex (Fig. 7).   
To elucidate if MtrC, MtrD and MtrE can form a stable tripartite efflux complex, we also 
constructed an MtrCDE fitting model based on our crystal structure of MtrE and structure of the 
predicted MtrCD complex.  After optimizing this docked model, the final structure of the 
MtrCDE complex suggests that the trimeric MtrE channel interacts with the tip of the -helical 
domain of the MtrC hexamer to generate an MtrE3-MtrC6-MtrD3 complex model that spans both 
the inner and outer membranes of the bacterial cell envelope (Fig. 7).  
It is possible that the outer membrane channel protein is able to directly interact with its 
corresponding multidrug efflux pump to form a complex (33).  The formation of this transporter-
channel complex may not require the presence of the corresponding membrane fusion protein.  
However, it has been demonstrated that the MtrC membrane fusion protein is needed to open the 
MtrE channel protein for drug export (38).  In addition, it has been shown that transport of metal 
ion by the CusA efflux pump becomes more efficient in the presence of the CusB membrane 
fusion protein (20). Therefore, it is anticipated that the presence of these membrane fusion 
proteins are required for fully functional efflux systems.  
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Discussion 
The United States Centers for Disease Control and Prevention (CDC) determined that, 
because of the advent of multidrug- and cephalosporin-resistant, it is prudent to monitor and 
encourage research antibiotic resistance in N. gonorrhoeae (39).  The structures of MtrD and 
MtrE provide an invaluable insight into the workings of antimicrobial-resistance conferring 
efflux pumps in N. gonorrhoeae. By studying the structures, new drugs and methods targeting 
the complex can be designed and tested.  
Some of the similarity of the MtrD structure with that of AcrB suggested a binding 
pocket within the large periplasmic cleft. We first ran a blind-docking study on the full 
monomer, and then concentrated on the best binding areas, which resulted in predicted binding at 
the area similar to AcrB. Of the 70,000 compounds screened, quinupristin and vancomycin were 
predicted as the best binding antibiotics. Looking at where the majority of the best binding 
ligands were predicted, it is possible that the flexible loop created by residues 608-619 may 
contribute to the recognition or extrusion of the ligand. 
The interactions between MtrD and MtrE have been reported; and with the two 
structures, we used RosettaDock to predict the interactions between MtrD and MtrE. The results 
suggest interactions between the α-hairpin between H7 and H8 of MtrE contacts the β-hairpin of 
subdomain DN in MtrD.  
     Since the crystal structure of MtrC is not yet available, we used the structure of MexA 
and the program I-TASSER to predict its structure. We then used it to assemble the tripartite 
structure of MtrCDE. After using RosettaDock, the docked model appears to suggest that the 
trimeric MtrE channel interacts with the tip of the α-helical domain of the MtrC hexamer. Of 
course, these are merely predictions, and further elucidations of the trimeric complex are needed.  
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Fig. 1a. 
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Fig. 1b. 
 
Fig. 1. Structure of the N. gonorrhoeae MtrD efflux pump.  (a) Ribbon diagram of a protomer of 
MtrD viewed in the membrane plane.  The molecule is colored using a rainbow gradient from the 
N-terminus (blue) to the C-terminus (red).  Sub-domains DN, DC, PN2, PC1 and PC2 are 
labeled.  The location of PN1 is behind PN2, PC1 and PC2.  (b) Ribbon diagram of the MtrD 
trimer viewed in the membrane plane.  Each subunit of MtrD is labeled with a different color.  
Residues 917-927 (only found in MtrD) forming the upper portion of TM9 and the loop 
connecting TM9 and TM10 are in blue color. 
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Fig 2. Sequence and topology of MtrD, AcrB and MexB.  Alignment of the amino acid 
sequences of MtrD, AcrB and MexB were done using CLUSTAL W.  *, identical residues; :, 
>60% homologous residues.  Secondary structural elements are indicated: TM, transmembrane 
helix; N and N, helix and strand, respectively, in the N-terminal half; C and C, helix and 
strand, respectively, in the C-terminal half.  The MtrE docking domain is divided into two sub-
domains, DN and DC; whereas the pore domain is divided into four sub-domains, PN1, PN2, 
PC1 and PC2.  The sequence and topology of MtrD are shown at the top. 
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Fig. 3a. 
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Fig. 3b. 
 
Fig. 3. Structure of the N. gonorrhoeae MtrE channel protein.  (a) Ribbon diagram of a protomer 
of MtrE viewed in the membrane plane.  The molecule is colored using a rainbow gradient from 
the N-terminus (blue) to the C-terminus (red).  (b) Ribbon diagram of the MtrE trimer viewed in 
the membrane plane.  Each subunit of MtrE is labeled with a different color. 
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Fig. 4. Secondary structural topology of the MtrE monomer.  The topology was constructed 
based on the crystal structure of MtrE.  The -helices and -strands are colored cyan and orange, 
respectively. 
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 Fig. 5. Docking of ligands onto the structure of MtrD.  This is a composite figure showing the 
predicted strongest multidrug-binding site of MtrD and the locations of the predicted bound 
ligands.  The ligands shown in stick models are UCL 1684 (red), naphthofluorescein (magenta) 
and 5(6)-carboxynaphthofluorescein (yellow).  The flexible loop created by residues 608-619 is 
colored blue.  It is suspected that this flexible loop may swing into this drug binding site to 
facilitate export during drug extrusion.  The rest of the secondary structural elements of MtrD are 
colored cyan. 
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Fig. 6. Docking of MtrE to MtrD.  The -hairpins at the periplasmic end of the MtrE trimer 
interacts with the -hairpins at the top of the periplasmic domain of the MtrD trimer.  The 
surface rendering of the MtrD3-MtrE3 complex is colored as follows: green, MtrE trimer; red, 
MtrD trimer (OM, outer membrane; IM, inner membrane). 
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Fig. 7. Predicted structural model of the MtrCDE tripartite efflux complex.  The -helical end of 
the MtrE channel is presumed to interact with the -helical hairpin of the MtrC membrane fusion 
protein in MtrCD to form the MtrCDE tripartite efflux complex.  The surface rendering of the 
MtrE3-MtrC6-MtrD3 complex is colored as follows: green, crystal structure of the MtrE trimer; 
blue, predicted structure of the MtrC hexamer; red, crystal structure of the MtrD trimer (OM, 
outer membrane; IM, inner membrane).    
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Fig. S1a. 
 
 
136 
 
 
Fig. S1b. 
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Fig. S1c. 
 
Fig. S1. Comparison of the structures of the MtrD and AcrB efflux pumps.  (a) Ribbon diagram 
of protomers of MtrD and AcrB viewed in the membrane plane.  This is a superimposition of a 
subunit of MtrD (red) onto an “access” protomer of AcrB (pdb: 2DHH) (green), indicating that 
the structures of these two efflux pumps are quite distinct.  Superimposition of these two 
structures result in a high RMSDs of 7.6 Å over 1,000 C

 atoms.  (b) Front view of the 
periplasmic clefts, formed by subdomains PC1 and PC2, of MtrD and AcrB.  The secondary 
structural elements of these two transporters are colored red (MtrD) and green (AcrB).  (c) 
Potential multidrug binding within the periplasmic cleft of MtrD.  The flexible loop created by 
residues 608-619 is colored blue.  This loop should correspond to the Phe-617 loop in AcrB.  It is 
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suspected that this flexible loop may swing into this drug binding site to facilitate export during 
drug extrusion.  The rest of the secondary structural elements of MtrD are colored red. 
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Fig. S2a. 
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Fig. S2b. 
 
Fig. S2. Predicted top ligands for the MtrD multidrug efflux pump.  (a) The top 10 antibiotics for 
the MtrD pump with respect to binding affinities.  (b) The top 9 small molecules for the MtrD 
pump with respect to binding affinities.  Each ligand is presented as follows: rank, name of the 
ligand, predicted binding affinity.  
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Table 1.  Data collection and refinement statistics.  
Data set MtrD 
   Data Collection         
Wavelength (Å) 0.98 
   Space group R32 
   Resolution (Å) 50 – 3.53 
   
 
(3.68-3.53) 
   Cell constants (Å) 
         a 152.99 
        b 152.95 
        c 360.74 
        α, β, γ (°) 90, 90, 120 
   Molecules in ASU 1 
   Redundancy 2.9 (2.9) 
   Total reflections 377,955 
   Unique reflections 20,296 
   Completeness (%) 97.7 (98.0) 
   Rsym (%) 7.7 (42.9) 
   I / σ(I) 17.16 (1.9) 
   Refinement 
 
            
Resolution (Å) 50 – 3.53 
   Rwork 27.9 
   Rfree  33.3 
   rms deviation from ideal 
            bond lengths (Å) 0.003 
           bond angles (°) 0.794 
   Ramachandran         
most favoured (%) 89.6 
   additional allowed (%) 10.1 
   generously allowed (%) 0.3 
   disallowed (%) 0 
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Table 2.  Data collection and refinement statistics.  
Data set 
 
MtrE 
  Data Collection         
Wavelength (Å) 
 
0.98 
  Space group 
 
P6322 
  Resolution (Å) 
 
50 – 3.29 
  
  
(3.41-3.29) 
  Cell constants (Å) 
         a 
 
93.89 
       b 
 
93.89 
       c 
 
391.54 
       α, β, γ (°) 
 
90, 90, 120 
  Molecules in ASU 
 
1 
  Redundancy 
 
3.4 (3.3) 
  Total reflections 
 
287,882 
  Unique reflections 
 
16,706 
  Completeness (%) 
 
98.7 (95.6) 
  Rsym (%) 
 
11.8 (43.5) 
  Rpim (%)  7.6 (30.2)   
Average I / (I) 
 
9.7 (2.4) 
  Refinement 
 
            
Resolution (Å) 
 
50 – 3.29 
  Rwork 
 
24.1 
  Rfree  
 
29.4 
  rms deviation from ideal 
            bond lengths (Å) 
 
0.009 
          bond angles (°) 
 
1.249 
  Ramachandran         
most favoured (%) 
 
96.8 
  additional allowed (%) 
 
3.2 
  generously allowed (%) 
 
0.0 
  disallowed (%) 
 
0.0 
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CHAPTER 5 
 Conclusions and further studies 
 Antibiotic resistance in bacteria is increasing, so there is much need to understand the 
resistance mechanisms in order to negate their efficacy. The efflux pumps in a bacterium confer 
resistance by removing the antimicrobial agents from within the cell and preventing it from 
reaching an effective concentration. The pumps themselves are obvious targets for inhibition, but 
they can also be inhibited by targeting their transcriptional regulator. By competing with the 
substrate for the regulator, the regulator stays bound to the DNA operon and prevents the efflux 
proteins from being expressed. The antimicrobial agent can then accumulate and once again be 
effective.   
 Drug screening, a familiar process in antimicrobial searches, is costly and time-intensive. 
Using computational methods allows the virtual screening of large libraries before investing in 
the experimental side. The drawback of virtual screening is that a structure is needed. Ideally, 
one would have a high-resolution structure with a known binding site. Of course, the conditions 
for crystallizing a protein may not be the correct conditions in vivo, altering the conformation or 
folding, but this is the danger of any experiment ex vivo. As a result, computational screening 
can elucidate some of the binding mechanisms and ligands but it must be tested experimentally.  
 We determined the crystal structures of the bound and apo-forms of Rv3066, the 
transcriptional regulator for the mmr gene from M. tuberculosis. Using these structures, we 
determined that the apo-Rv3066 dimeric regulator binds to an area of DNA upstream of the 
mmr-Rv3066 operon at a 14-bp palindromic inverted repeat. The binding pocket recognizes the 
ethidium substrate and forms a cage around the molecule with stacking and hydrophobic 
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interactions. This causes a conformational change in the protein that interferes with its ability to 
bind to the major grooves of the DNA.  
 These structures were especially useful for docking various ligands using AutoDock 
Vina. The ethidium molecule was removed from the structure and allowed to dock blindly onto 
the monomer. The program was able to predict the binding pocket. The predicted bound 
ethidium overlapped with the actual bound ethidium, showing that the program can be used to 
predict how different molecules would interact with the binding pocket of Rv3066. Acriflavine, 
proflavine, pyronin Y, safranin O and thioridazine were predicted to be in a similar area to the 
ethidium-bound structure. 
 The CusCBA system in E. coli is a HME-RND pump consisting of the CusA transporter 
in the inner membrane, the adaptor protein CusB in the periplasm, and the outer membrane 
protein CusC. CusF is a periplasmic protein that chaperones ions to the CusCBA complex. The 
entire system spans the full cell envelope and, driven by the proton motive force, expels the 
metal ions Cu(I) and Ag(I). With the crystal structures of these proteins, we were able to 
determine how the metal ion is shuttled through the complex, and how the tripartite complex 
may form. Through directed mutagenesis, we were able to show that certain residues were 
important for the movement of the metal ion.   
 MtrD is another RND protein. In N. gonorrhoeae, the MtrD protein is part of the 
MtrCDE complex that confers resistance to various drugs, dyes, and fatty acids. We determined 
the crystal structure of MtrD as a homotrimer with a structure similar to AcrB. Using several 
curated databases, we found that most potential ligands preferred to bind to the pocket that is 
similar to the AcrB periplasmic vestibule. Interestingly, we found that the fatty acids were not 
predicted to bind well to MtrD.  This may be due to the fact that the FarA-FarB-MtrE system is 
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mainly responsible for the extrusion of fatty acids, or that the apo-structure was not sufficient to 
determine the binding site for fatty acids. Future studies would ideally have the bound structure. 
 The crystal structure of a protein or protein complex can reveal many secrets about the 
workings of efflux pumps. By studying how the protein changes conformation in the presence of 
a substrate, or how a substrate binds to the protein, we can determine how substrates are 
recognized and how they are moved towards the exterior of the cell. By knowing the structure of 
the transcriptional regulator, we can predict how it would react to similar substrates, or new 
substrates.  
 The motivation for studying the efflux pumps in bacteria is to determine a way to inhibit 
its efficacy at conferring resistance to the bacterium. As one of the major methods used by 
antibiotic-resistance bacteria, understanding the mechanisms will allow us to design new 
substrates that will wither block the efflux channel or prevent the transcriptional regulator from 
recognizing its substrate. Virtual docking will allow us to speed up the process of screening for 
binding ligands, but it is still an imprecise method. Future studies would entail testing the 
predicted ligand in an experimental setting in order to determine if it does bind to the protein, 
and if it can abolish the bacterium’s resistance. 
 Abolishing antibiotic-resistance in bacteria is critical due to the rise of multi-drug 
resistant strains of bacteria. Already, we are seeing strains that either are completely resistant to 
treatment, or only respond to treatments with severe side effects. The research and development 
pipeline for new drugs is long and expensive; if the cause of the resistance can be stopped, then 
the old antibiotics can be used again to treat bacterial infections. Due to the efflux pumps’ 
involvement in other cell resistance, such as conferring drug-resistance to cancer cells, 
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understanding how these proteins work and how to impede their function is of great clinical 
value.    
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